<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004270.pub2" GROUP_ID="HAEMATOL" ID="822403032618150278" MERGED_FROM="" MODIFIED="2012-03-13 12:58:30 +0100" MODIFIED_BY="Andrea Will" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2012-03-13 12:58:30 +0100" MODIFIED_BY="Andrea Will">
<TITLE>Purine Antagonists for Chronic Lymphocytic Leukaemia</TITLE>
<CONTACT>
<PERSON ID="18256" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Steurer</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>michael.steurer@i-med.ac.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Haematology &amp; Oncology</DEPARTMENT>
<ORGANISATION>Innsbruck University Hospital</ORGANISATION>
<ADDRESS_1>Anichstrasse 35</ADDRESS_1>
<ADDRESS_2/>
<CITY>A-6020 Innsbruck</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43 512 504 0</PHONE_1>
<PHONE_2>+43 512 504 ext: 81386</PHONE_2>
<FAX_1>+43 512 5045615</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-03-13 11:56:53 +0100" MODIFIED_BY="Andrea Will">
<PERSON ID="18256" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Steurer</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>michael.steurer@i-med.ac.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Haematology &amp; Oncology</DEPARTMENT>
<ORGANISATION>Innsbruck University Hospital</ORGANISATION>
<ADDRESS_1>Anichstrasse 35</ADDRESS_1>
<ADDRESS_2/>
<CITY>A-6020 Innsbruck</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43 512 504 0</PHONE_1>
<PHONE_2>+43 512 504 ext: 81386</PHONE_2>
<FAX_1>+43 512 5045615</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13773" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Georg</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pall</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>georg.pall@uki.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>University Clinic Innsbruck</ORGANISATION>
<ADDRESS_1>Anichstrasse 35</ADDRESS_1>
<ADDRESS_2/>
<CITY>Innsbruck</CITY>
<ZIP>6020</ZIP>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43 512 504 0</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17217" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sue</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Richards</LAST_NAME>
<SUFFIX>Dr Phil</SUFFIX>
<POSITION>Senior Statistician</POSITION>
<EMAIL_1>sue.richards@ctsu.ox.ac.uk</EMAIL_1>
<EMAIL_2>suerichardsnow@yahoo.co.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE>+44 77 9936 4371</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Clinical Trials Services Unit</DEPARTMENT>
<ORGANISATION>Oxford University</ORGANISATION>
<ADDRESS_1>Woodstock Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Oxford</CITY>
<ZIP>OX2 6HE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1865 743 863</PHONE_1>
<PHONE_2>+44 1685 881936</PHONE_2>
<FAX_1>+ 44 1865-743986</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5936" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Guido</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schwarzer</LAST_NAME>
<SUFFIX/>
<POSITION>Statistician</POSITION>
<EMAIL_1>sc@imbi.uni-freiburg.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>German Cochrane Centre</DEPARTMENT>
<ORGANISATION>Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg</ORGANISATION>
<ADDRESS_1>Stefan-Meier-Str. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>Freiburg</CITY>
<ZIP>D-79104</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 761 203 6668</PHONE_1>
<PHONE_2/>
<FAX_1>+49 761 203 6680</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19365" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Julia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bohlius</LAST_NAME>
<SUFFIX>MScPH</SUFFIX>
<POSITION/>
<EMAIL_1>jbohlius@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>jbohlius@ispm.unibe.ch</EMAIL_2>
<URL>www.chmg.de</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>0041 31 631 3510</PHONE_1>
<PHONE_2/>
<FAX_1>0041 31 631 3524</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13761" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Richard</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Greil</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>r.greil@salk.at</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Third Mediacl Deapartment</DEPARTMENT>
<ORGANISATION>St. Johann Hospita - Paracelsus University</ORGANISATION>
<ADDRESS_1>Muellner Hauptstrasse 48</ADDRESS_1>
<ADDRESS_2/>
<CITY>Salzburg</CITY>
<ZIP>5020</ZIP>
<REGION/>
<COUNTRY CODE="AT">Austria</COUNTRY>
<PHONE_1>+43 662 4482 2879</PHONE_1>
<PHONE_2/>
<FAX_1>+43 662 4482 2898</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-05 14:59:06 +0100" MODIFIED_BY="Nicole Skoetz">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="5" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-03-13 12:58:30 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-13 12:58:30 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Additional tables linked to text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-03-13 12:57:34 +0100" MODIFIED_BY="Nicole Skoetz">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-13 12:57:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Universitätsklinik für Innere Medizin, Abteilung für Hämatologie &amp; Onkologie, Innsbruck</NAME>
<COUNTRY CODE="AT">Austria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Tiroler Krebsforschungsinstitut an der Universität Innsbruck</NAME>
<COUNTRY CODE="AT">Austria</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Editorial Base of CHMG is funded by the German Ministry of Education and Research (BMBF)</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-03-13 12:06:40 +0100" MODIFIED_BY="Nicole Skoetz">
<SUMMARY MODIFIED="2008-11-05 15:02:48 +0100" MODIFIED_BY="Nicole Skoetz">
<TITLE MODIFIED="2008-11-05 15:02:48 +0100" MODIFIED_BY="Nicole Skoetz">Purine Antagonists for Chronic Lymphocytic Leukaemia</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-05 15:02:36 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Despite increasing insight into its tumour biology B-CLL remains an incurable disease. So far, chemotherapy with alkylating agents such as chlorambucil has been the mainstay of treatment in B-CLL. However, purine antagonists such as fludarabine are increasingly being used, as it has been suggested that these novel drugs are more effective. This review confirms the greater response rates achievable by using purine antagonists but at the cost of greater toxicity, mainly infections. There is inconclusive evidence whether treatment with purine antagonists improves survival. None of the studies included quality of life data. More research is needed to fully explore the role of purine antagonists in the treatment of B-CLL and their potential impact on survival.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-05 15:02:30 +0100" MODIFIED_BY="Nicole Skoetz">
<ABS_BACKGROUND>
<P>Recent trials suggest improved response rates for purine antagonists compared to alkylator-based regimens in the treatment of B-CLL. However, none was able to show a survival advantage. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine if there is any advantage of purine antagonists compared to alkylating agents (alone or in combination) in the treatment of patients with previously untreated B-CLL. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-05 14:59:30 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Medical databases (Cochrane Library, MEDLINE, EMBASE), conference proceedings and internet-based trial registers were searched electronically and/or by hand (1990 to 2003). All references were checked for further trial information. We also contacted experts in the field and pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing purine antagonists as single agents with alkylator-based regimens in patients with previously untreated B-CLL were included. We included full-text and abstract publications as well as unpublished data. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-05 14:59:35 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Data extraction and quality assessment were done in duplicate by two independent reviewers. Missing data were obtained from original authors. Endpoints included overall survival, overall response rate, rate of complete remissions, progression-free survival, treatment-related morbidity and mortality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-05 15:02:25 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Five trials with 1838 randomised patients were included. There is some evidence for improved overall survival after treatment with purine antagonists compared to alkylators, but statistical significance was not reached (HR 0.89 [95% CI 0.78 to 1.01], 4 trials, N = 1638). However, the relative risk for achieving an overall response (RR 1.22 [95% CI 1.13 to 1.31], 5 trials, N = 1751) and complete remission (RR 1.94 [95% CI 1.65 to 2.28], 5 trials, N = 1751) was significantly higher, resulting in a longer progression-free survival (HR 0.70 [95% CI 0.61 to 0.82], 4 trials, N = 1638). Incidence of grade III/IV infections was significantly higher in patients receiving treatment with purine antagonists (RR 1.83 [95% 1.30 to 2.58], 4 trials, N = 1620). There was no significant difference concerning the relative risk for grade III/IV neutropenia (RR 1.14 [95% CI 0.98-1.34], 4 trials, N = 1620) and therapy-related mortality (RR 0.94 [95% CI 0.45 to 1.95]). Overall incidence of haemolytic anaemia was low, but significantly increased in the purine antagonist group (RR 3.36 [95% CI 1.27 to 8.91], 3 trials, N = 1258).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-05 15:02:30 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Despite significantly increased overall response and complete remission rates and longer progression-free survival with first-line treatment of B-CLL patients with single-agent purine antagonists, we were not able to detect a statistically significant improvement of overall survival compared to alkylator-based regimens. Furthermore, the use of purine antagonists also augments the risk for grade III/IV infections and haemolytic anaemia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-03-13 12:06:40 +0100" MODIFIED_BY="Nicole Skoetz">
<BACKGROUND MODIFIED="2008-11-05 15:10:42 +0100" MODIFIED_BY="Nicole Skoetz">
<P>With an incidence of about 3 to 6/100,000 persons per year, chronic lymphocytic leukaemia (CLL) is a common malignant hematopoietic disorder causing a considerable burden of morbidity and mortality (<LINK REF="REF-Cartwright-1990" TYPE="REFERENCE">Cartwright 1990</LINK>). It is characterized by the clonal proliferation of highly differentiated but immuno-incompetent lymphocytes spreading in the lymphatic and hematopoietic system causing lymphocytosis, enlargement of lymph nodes, hepatosplenomegaly as well as anaemia and thrombocytopenia by suppression of regular hematopoiesis. In more than 97% of cases the malignant clone is of B-cell-origin. The remaining 3% are of T-cell lineage and considered as an entity completely different from B-CLL, especially concerning therapy (<LINK REF="REF-Kipps-1995" TYPE="REFERENCE">Kipps 1995</LINK>). Thus, in this review T-CLL will be excluded.<BR/>Usually, the natural course of the disease is characterized by a slow, often asymptomatic progression over several years although considerable variations can be observed (<LINK REF="REF-Rozman-1995" TYPE="REFERENCE">Rozman 1995</LINK>). Known and frequent complications are infections due to secondary hypogammaglobulinemia and granulocytopenia, as well as autoimmune phenomena such as haemolytic anaemia or thrombocytopenia, or secondary transformation into high-grade lymphomas.<BR/>Two different staging-systems have been developed and are widely accepted (<LINK REF="REF-Rai-1975" TYPE="REFERENCE">Rai 1975</LINK>; <LINK REF="REF-Binet-1981" TYPE="REFERENCE">Binet 1981</LINK>).</P>
<P>1) Rai Staging System:</P>
<UL>
<LI>Stage 0: absolute lymphocytosis (&gt;15,000 per cubic millimeter) without lymphadenopathy, hepatosplenomegaly, anaemia, or thrombocytopenia.</LI>
<LI>Stage I: absolute lymphocytosis with lymphadenopathy without hepatosplenomegaly, anaemia, or thrombocytopenia.</LI>
<LI>Stage II: absolute lymphocytosis with either hepatomegaly or splenomegaly, with or without lymphadenopathy.</LI>
<LI>Stage III: absolute lymphocytosis and anaemia (haemoglobin &lt;11 g/dL) with or without lymphadenopathy, hepatomegaly, or splenomegaly.</LI>
<LI>Stage IV: absolute lymphocytosis and thrombocytopenia (&lt;100,000 per cubic millimeter) with or without lymphadenopathy, hepatomegaly, splenomegaly, or anaemia.</LI>
</UL>
<P>2) Binet Staging System:</P>
<UL>
<LI>Stage A: no anaemia or thrombocytopenia and fewer than three areas of lymphoid involvement</LI>
<LI>Stage B: three or more areas of lymphoid involvement without anaemia or thrombocytopenia</LI>
<LI>Stage C: anaemia and/or thrombocytopenia regardless of the number of areas with lymphoid enlargement.</LI>
</UL>
<P>According to the revised National Cancer Institute (NCI) Working Group guidelines (<LINK REF="REF-Cheson-1996" TYPE="REFERENCE">Cheson 1996</LINK>), treatment should be initiated if </P>
<UL>
<LI>the disease progresses to Rai stage III or Binet stage C,</LI>
<LI>in case of infectious or autoimmune complications as mentioned above,</LI>
<LI>if lymphocyte doubling time is less than 12 months or</LI>
<LI>if the patient becomes symptomatic in terms of night sweats, weight loss or fever ("B-symptoms").</LI>
</UL>
<P>A recently published meta-analysis performed by the The CLL Trialists' Collaborative Group (<LINK REF="REF-CLL-Trialists_x0027_-Group" TYPE="REFERENCE">CLL Trialists' Group</LINK>) and a systematic overview reported by The Swedish Council of Technology Assessment in Health Care (<LINK REF="REF-Kimby-2001" TYPE="REFERENCE">Kimby 2001</LINK>) provide substantial evidence, that early treatment is not associated with a better outcome compared to deferred treatment. Thus, it is generally recommended not to treat patients with early stage disease unless there are clear signs of progression.<BR/>Several cytotoxic agents have proven efficacy in the treatment of B-CLL. The alkylating agent chlorambucil (as monotherapy or in combination with steroids) has been considered the mainstay of treatment and the standard first-line therapy of B-CLL over years. Nowadays, combination therapies including cyclophosphamide, vincristine, anthracyclines and prednisone (COP, CHOP, CAP) are widely used. In a comparison of chlorambucil with COP (cyclophosphamide, vincristine, and prednisone), the latter proved to produce a slightly higher overall-response rate but there was no difference as far as overall survival was concerned (<LINK REF="REF-FCG-on-CLL-1990" TYPE="REFERENCE">FCG on CLL 1990</LINK>).). These data are supported by the reports of The CLL Trialists' Collaborative Group and Kimby et al., demonstrating that despite improved response rates there is no evidence for a survival benefit for patients from alkylator-based polychemotherapy compared to single-drug treatment or the addition of anthracyclines (<LINK REF="REF-CLL-Trialists_x0027_-Group" TYPE="REFERENCE">CLL Trialists' Group</LINK>; <LINK REF="REF-Kimby-2001" TYPE="REFERENCE">Kimby 2001</LINK>).<BR/>In the early 1990's a novel class of drugs was introduced in the treatment of B-CLL: the purine antagonists such as fludarabine, cladribine or pentostatin. The drug most widely applied is intravenous fludarabine which was shown to be an efficient first- and second-line drug in terms of overall survival, response rates, progression-free survival and time to re-treatment in several phase II studies (<LINK REF="REF-Keating-1989" TYPE="REFERENCE">Keating 1989</LINK>). In general, purine antagonists are well tolerated. However, compared to classic cytotoxic drugs, purine antagonists produce a different pattern of side effects including opportunistic infections due to suppression of T-helper-lymphocytes and haemolytic anaemia (<LINK REF="REF-CCO-2002" TYPE="REFERENCE">CCO 2002</LINK>).<BR/>Although several trials suggest improved response rates with the use of purine antagonists (Johnson 1996; <LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>; <LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>), none was able to show a survival advantage. Thus, a Cochrane systematic review may be able to provide more definitive evidence for the role of purine antagonists in the treatment of B-CLL.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine if there is any advantage of purine antagonists compared to alkylating agents (alone or in combination) in the treatment of previously untreated B-CLL in terms of overall survival, response rates, quality of life, therapy-related morbidity and mortality.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-05 15:21:28 +0100" MODIFIED_BY="Nicole Skoetz">
<SELECTION_CRITERIA MODIFIED="2008-11-05 15:11:16 +0100" MODIFIED_BY="Nicole Skoetz">
<CRIT_STUDIES MODIFIED="2008-11-05 15:07:53 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Randomised controlled trials with or without blinding comparing purine antagonists as monotherapy to alkylating agents (alone or in combination). Abstract and unpublished data were included, if sufficient information on study design, characteristics of participants, interventions and outcomes were available. Otherwise they were included with reservations only. Considering the fact that there are ongoing but yet unpublished phase III trials exploring the activity of purine antagonists in combination with other cytostatic agents and/or monoclonal antibodies, we intend to include these types of studies in an update, which is due within two years after completion of this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-05 15:08:00 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Adults (&gt;18 years) diagnosed with previously untreated chronic B-lymphocytic leukaemia using clinical and histological criteria defined by the NCI-Sponsored Working Group (<LINK REF="REF-Cheson-1988" TYPE="REFERENCE">Cheson 1988</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Comparison of purine antagonists with alkylating agents (alone or in combination) in the treatment of previously untreated B-CLL .</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-05 15:11:16 +0100" MODIFIED_BY="Nicole Skoetz">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-05 15:11:16 +0100" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>Overall survival</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-05 15:11:04 +0100" MODIFIED_BY="Nicole Skoetz">
<UL>
<LI>Response to treatment, i.e. overall response (OR: complete + partial response rates), complete response (CR), and partial response (PR)</LI>
<LI>Time to re-treatment</LI>
<LI>Progression-free survival</LI>
<LI>Therapy-related morbidity and mortality</LI>
<LI>Quality of life.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-05 15:19:22 +0100" MODIFIED_BY="Nicole Skoetz">
<P>All searches were conducted for publications in the period between January 1990 to December 2003, as we did not anticipate any published data before that date. Starting in January 2004, publications available by the data sources stated below were scrutinized on a regular basis and relevant information was extracted. Citations of all trials identified were checked for additional references.</P>
<P>Relevant trials in any language were identified through electronic searches and searching other resources.</P>
<ELECTRONIC_SEARCHES MODIFIED="2008-11-05 15:18:20 +0100" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Electronic databases:</B> </P>
<UL>
<LI>Cochrane Controlled Trials Register (CENTRAL) </LI>
<LI>MEDLINE (1990 to 2003) (for search strategy: see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, this search strategy was adapted to the requirements for the different databases)</LI>
<LI>CancerLit (1990 to 2003) </LI>
<LI>EMBASE (1990 to 2003)</LI>
</UL>
<P>
<B>Databases of ongoing trials</B>:</P>
<UL>
<LI>www.controlled-trials.com</LI>
<LI>http://clinicaltrials.nci.nih.gov</LI>
<LI>http://clinicaltrials.gov/ct/gui</LI>
<LI>www.eortc.be</LI>
<LI>www.ctc.usyd.edu.au</LI>
<LI>www.trialscentral.org/index.html</LI>
</UL>
<P>
<B>Electronic searching of the conference proceedings </B>
</P>
<UL>
<LI> American Society of Hematology (1998 to 2002) </LI>
<LI> American Society of Clinical Oncology (1997 to 2003).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-05 15:19:22 +0100" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Hand-searching</B>
<BR/>Citation from identified trials and relevant review articles.</P>
<P>
<BR/>
<B>Conference proceedings </B>
</P>
<UL>
<LI>American Society of Hematology (1990 to 1997)</LI>
<LI>American Society of Clinical Oncology (1990 to 1996)</LI>
<LI>International Conference on Malignant Lymphoma Meetings (1990 to 2002) </LI>
<LI>International Workshop on CLL (IWCLL) (1990 to 2003)</LI>
<LI>Conference proceedings of the International Society of Hematology (ISH) (1990 to 2003)</LI>
<LI>European Haematology Association (EHA) (1990 to 2003)</LI>
</UL>
<P>
<B>Contact </B>
</P>
<UL>
<LI>Groups or individuals who may have done randomised trials in CLL</LI>
<LI>Producers of Purine antagonists (Schering AG, Germany; Janssen-Cilag, Austria; Wyeth, Germany)</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-05 15:21:28 +0100" MODIFIED_BY="Nicole Skoetz">
<P>
<B>TRIALS SELECTION</B>
</P>
<P>Titles and abstracts of studies identified by the literature search were screened independently by two reviewers (G.P., M.S.) for eligibility according to the criteria stated previously. If this could not be done satisfactorily from the title or the abstract, a full text version was obtained for assessment. Studies apparently meeting the inclusion criteria were assessed further with an eligibility form. In brief, this form addressed the following questions:</P>
<UL>
<LI>Is the study described as randomised?</LI>
<LI>Did the participants in the study have B-CLL according to the criteria defined by the NCI-sponsored Working Group (<LINK REF="REF-Cheson-1988" TYPE="REFERENCE">Cheson 1988</LINK>)?</LI>
<LI>Was a purine antagonist tested against a protocol containing alkylating agents?</LI>
<LI>Were the participants adults (&gt;18 years)?</LI>
</UL>
<P>Eligible studies had to meet all these criteria. If there was insufficient information concerning eligibility, the corresponding author was contacted for clarification. Any disagreement among the reviewers was solved by discussion. Any duplicate reports as well as trials concerning induction regimens for allogeneic or autologous bone marrow or stem cell transplantation were excluded.For all eligible studies full text versions were obtained for quality assessment and data extraction.</P>
<P>
<B>QUALITY ASSESSMENT</B>
</P>
<P>The quality of eligible studies was assessed independently by two reviewers (G.P., M.S.) in an unblinded fashion using the full text article. Any disagreements were discussed together with R.G. and J.B. until consensus was obtained. Quality was evaluated using an assessment form designed for the topic of this review. The following criteria were considered:</P>
<OL>
<LI>Was the randomisation method satisfactory?</LI>
<LI>Was the treatment allocation concealed (e.g., central randomisation)?</LI>
<LI>Was the treatment allocation masked from the patients?</LI>
<LI>Was the treatment allocation masked from the clinicians?</LI>
<LI>Was the number of withdrawals, dropouts and loss to follow-up in each group stated?</LI>
<LI>Was an intention-to-treat-analysis performed?</LI>
<LI>Were criteria stated concerning re-treatment at the time of relapse or progressive disease, respectively?</LI>
</OL>
<P>For any criterion that was unclear, the corresponding author of the study was contacted.<BR/>The influence of study quality on the treatment effect was explored in sensitivity analyses.</P>
<P>
<B>DATA EXTRACTION</B>
</P>
<P>Data concerning details of study population, intervention and outcomes was extracted independently by two reviewers (G.P., M.S.) using a standardized data extraction form; disagreements were resolved by discussion. This form included the following items:</P>
<OL>
<LI>General information: title, authors, source, contact address, country, language, year of publication, duplicate publications, sponsoring and setting of trial</LI>
<LI>Trial characteristics including design, sample size, randomisation method, concealment of allocation, blinding of patients and clinicians, withdrawals, median length of follow-up, losses to follow-up</LI>
<LI>Interventions: dose, route, timing, co-medications</LI>
<LI>Patients: sampling, exclusion criteria, baseline characteristics, similarity of groups at baseline (concerning basic demographic data, distribution of age, stage, performance status), diagnostic criteria</LI>
<LI>Outcomes: response criteria applied, measures as stated previously</LI>
<LI>Retreatment: definition for initiation of re-treatment</LI>
<LI>Statistics: type of analysis (intention to treat versus per protocol analysis)</LI>
</OL>
<P>To obtain any unreported data we contacted the corresponding author of the study for clarification.</P>
<P>
<B>DATA ANALYSIS</B>
<BR/>Statistical analyses were conducted with RevMan 4.2.5 and R, Version 1.9.1 (<LINK REF="REF-Ihaka-1996" TYPE="REFERENCE">Ihaka 1996</LINK>). A fixed effects model was used in all meta-analyses. To estimate time to event data, such as overall survival, time to re-treatment, time to progression, hazard ratios (HR) were calculated. If HR was not stated in the original publication, they were calculated by extracting and analysing data from the published survival curves using methods described by Parmar et al. (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>). For binary data, such as response to treatment (OR, CR, PR), the relative risk (RR) was used to evaluate the treatment effect. Numbers needed to treat (NNT) and numbers needed to harm (NNH) were calculated for the ease of interpretation.<BR/>Heterogeneity of treatment effects between trials was tested using a chi-squared statistic with significance being set at P &lt; 0.05. Expected causes of heterogeneity and the robustness of the overall results was assessed by sensitivity and subgroup analyses as described below. In meta-analyses with at least four trials, a funnel plot was generated and a linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) was performed to examine the likely presence of bias in meta-analysis. A p-value less than 0.1 was considered significant for the linear regression test.</P>
<P>
<B>SENSITIVITY ANALYSIS &amp; SUBGROUP ANALYSIS</B>
<BR/>There is some evidence that the following factors might cause heterogeneity. On these factors we planned to performed a sensitivity analysis and/or a subgroup analysis:</P>
<P>
<I>
<B>Sensitivity analysis:</B>
</I>
<BR/>
</P>
<UL>
<LI>Quality of studies</LI>
<LI>Retreatment strategies</LI>
<LI>Type of analysis (ITT vs. per protocol)</LI>
<LI>Crossover design of studies</LI>
</UL>
<P>However, due to the lack of relevant data, we were only able to perform sensitivity analyses on study quality.</P>
<P>
<I>
<B>Subgroup analysis:</B>
</I>
<BR/>
</P>
<UL>
<LI>Type of purine antagonist administered (Fludarabine, Cladribine or Pentostatine)</LI>
<LI>Type of alkylator-based regimen used as comparator (chlorambucil, CAP or CHOP)</LI>
<LI>Administration of prophylactic antibiotics during chemotherapy.</LI>
<LI>Administration of prophylactic antiemetic drugs.</LI>
<LI>Administration of prophylactic granulocyte colony-stimulating factor (G-CSF)</LI>
<LI>Age</LI>
<LI>Stage</LI>
</UL>
<P>We were only able to perform subgroup analyses on the type of purine antagonist, type of alkylator-based regimen as comparator and stage of disease. For all other criteria, there were no relevant data available.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-03-13 12:06:40 +0100" MODIFIED_BY="Nicole Skoetz">
<STUDY_DESCRIPTION MODIFIED="2012-03-13 12:03:00 +0100" MODIFIED_BY="Nicole Skoetz">
<P>A total of 329 potentially relevant titles were screened for inclusion (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Out of nine eligible studies, five trials with 1838 randomised patients were ultimately analysed. Whereas four trials were fully published (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>; <LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>; <LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>; <LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>), one study has only been reported in abstract form and according to the authors no further data are presently available (<LINK REF="STD-Spriano-1999" TYPE="STUDY">Spriano 1999</LINK>). Three trials were closed only recently and have not been fully evaluated yet, i.e. German <LINK REF="STD-CLL5" TYPE="STUDY">CLL5</LINK> trial (<LINK REF="STD-CLL5" TYPE="STUDY">CLL5</LINK>), International Phase III trial on B-CLL (<LINK REF="STD-Int.-Phase-III-trial" TYPE="STUDY">Int. Phase III trial</LINK>), and the British MRC4 trial (<LINK REF="STD-MRC-CLL4" TYPE="STUDY">MRC CLL4</LINK>). One trial had to be excluded as published results were pooled with data from non-randomised patients and none of the contacted authors responded to our repeated data clarification requests (<LINK REF="STD-Jaksic-2000" TYPE="STUDY">Jaksic 2000</LINK>).</P>
<P>Baseline characteristics of the five trials included in this analysis are listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. In total, 1838 patients were randomly assigned to receive either alkylator-based therapy or purine antagonist treatment. There was no blinded study. The types of comparators varied greatly from chlorambucil in different dosing schedules (with or without steroids) to anthracycline-containing regimens such as CAP or CHOP. Crossover of treatment arms was possible in four trials. As we primarily intended to investigate the effect of purine antagonists without additional cytostatic and/or monoclonal antibodies on previously untreated patients, we excluded the fludarabine-plus-chlorambucil treatment arm of the trial reported by Rai et al. (<LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>) from analyses as well as the subgroup of pretreated patients in the trial reported by the FCG (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>). In the three-armed study reported by Leporrier et al. patients were randomised to receive either fludarabine, CHOP or CAP. The CAP arm, however, was closed prematurely due to lower response rates at a planned interim analysis. As a consequence, patient numbers in the CAP arm are markedly lower (N = 237) than those in the fludarabine (N = 336) and CHOP (N = 351) arms. For analysis of this trial, results observed in the fludarabine arm were compared with the combined data obtained from all patients in both the CHOP and CAP arms. For analysis of overall response rates, results from the fludarabine arm were also analysed separately with those obtained from each alkylator regimen. Due to the premature closure of the CAP arm, reported results including this group contain an element of historical comparison because patients were not entered into the 3 arms over the same period of time. If individual patient data is obtained in the future for a meta-analysis, analyses will be stratified by time period to correct for this.<BR/>The trials displayed marked differences not only in general study design but also concerning inclusion and exclusion criteria, re-staging modalities, definitions of response criteria and definition of progression-free survival (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). As depicted in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, the maximal duration of treatment varied from six to 12 cycles of chemotherapy. Concerning response evaluation we also observed great heterogeneity from monthly (<LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>) to three- (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>; <LINK REF="STD-Spriano-1999" TYPE="STUDY">Spriano 1999</LINK>) or six-monthly (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>) re-staging procedures. In the three-armed study reported by Leporrier et al., re-staging in the CHOP arm was not performed until six cycles had been administered, whereas patients receiving treatment with CAP or fludarabine underwent re-staging every three cycles (<LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>). Staging criteria varied from application of the 1989 NCI criteria to those of 1996, which were, as in one study, subject to modifications in terms of excluding available radiological findings from response evaluation. Notably, measuring progression-free survival was also subject to varying definitions, rendering this study endpoint very difficult to compare between the individual trials (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). A clear-cut re-treatment strategy for relapse after study completion was given in one trial only (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>) implicating a very high risk of bias for comparing the outcome "time to re-treatment" which has also been reported in just one additional trial (<LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>).<BR/>None of these studies measured quality of life directly. There is one publication describing a retrospective quality-of-life-adjusted survival analysis according to the Q-TWIST method for patients in the study reported by Leporrier et al. (<LINK REF="REF-Levy-2001" TYPE="REFERENCE">Levy 2001</LINK>). However, as this is a surrogate analysis not involving individual patient data from to quality of life questionnaires, we decided not to include this report in our study.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Three of the four trials published in peer-reviewed journals fulfilled all of the seven quality criteria required. However, in the study published by Robak 21 patients (8%) were lost to follow-up (7 in the cladribine arm vs. 14 in the control arm) and excluded from data analyses (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). Therefore, this study did not meet the standards required for an ITT analysis. One study was reported as abstract only but despite contacting the authors we did not succeed in obtaining additional information on design and trial conduct. Therefore, this study was assessed as bearing a high risk of bias (<LINK REF="STD-Spriano-1999" TYPE="STUDY">Spriano 1999</LINK>). For three trials we obtained additional study data from the study authors (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>; <LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>; <LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-03-13 12:06:40 +0100" MODIFIED_BY="Nicole Skoetz">
<P>
<B>Overall survival</B>
<BR/>Data on overall survival were available in four trials including 1638 patients. No survival data were available from the trial reported by Spriano et al. (<LINK REF="STD-Spriano-1999" TYPE="STUDY">Spriano 1999</LINK>). Compared to alkylator-based regimens, treatment with purine antagonists was associated with a relative improvement of overall survival of 11% (HR 0.89; 95% CI 0.78 to 1.01; P = 0.07), but this difference was not statistically significant (figure 01.01). Funnel plot and linear regression test according to Egger (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) confirmed the absence of publication bias (P = 0.6) and there was no significant heterogeneity (P = 0.3). No difference in the effect of treatment on overall survival was detectable between subgroups according to stage (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>
<B>Overall response</B>
<BR/>Data on overall response were available for five studies including 1751 patients (figure 01.02). The response rates were significantly higher with the use of purine antagonists compared with alkylator-based regimens (RR 1.22; 95% CI 1.13 to 1.31; P &lt; 0.00001). The response rate in the control group was 60% (range 37 to 71%). For patients with this level of risk, eight would have to be treated with purine antagonists to obtain one additional response compared to alkylator-based therapy (NNT = 7.7; 95% CI 5.9 to 12.5). A potential publication bias was ruled out by calculating funnel plots and linear regression test (P=0.4) but we detected significant heterogeneity between the results of the individual trials (P &lt; 0.0001). To further characterize heterogeneity, sensitivity analyses were performed regarding study quality as given by the publication type (full text publications, i.e., low risk of bias vs. abstract publications, i.e.,high risk of bias) and the type of purine antagonist administered (fludarabine vs. cladribine) . Heterogeneity of results may in part be due to the type of purine antagonist applied as the overall response rate reported in the cladribine trial was significantly increased compared with the four trials applying fludarabine (P = 0.002, figure 01.11). Moreover, the choice of alkylator-based protocol in the control arm may also cause heterogeneity. Accordingly, in the subgroup analysis according to the type of alkylator therapy (figure 01.15) there was significant heterogeneity between subgroups (P &lt; 0.0005). We observed a significantly greater overall response rate for purine antagonists compared to CAP (RR 1.22; 95% CI 1.07 to 1.38) and chlorambucil (RR 1.44; 95% CI 1.14 to 1.32), but not when compared to CHOP (RR 1.0) which, however, was applied in one trial only. Heterogeneity was still present in the chlorambucil comparison subgroup, which may be attributable to different dosing ranging from 40mg/m<SUP>2</SUP>/month (<LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>) to 84mg/m<SUP>2</SUP>/month (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). Study quality as assessed by the criteria stated above, had no statistically significant influence on overall response (P = 0.09, figure 01.09). We further aimed to evaluate the treatment effects according to stage of the disease. Response rates according to stage were available for four studies including 1609 patients (figure 01.13). Significantly higher overall responses were observed with purine antagonists in high-risk patients as defined by Rai stages III &amp; IV and Binet stage C (RR 1.40; 95% CI 1.19 to 1.65) as well as in standard-risk patients i.e., Rai stages 0 to II, Binet A &amp; B (RR 1.19; 95% CI 1.10 to 1.29). Again, there was a significant degree of heterogeneity among the results of the individual trials (P = 0.006 and P = 0.0007, respectively). However, no heterogeneity between subgroups was detected (P = 0.24).</P>
<P>
<B>Complete response</B>
<BR/>Data on complete responses were available for five studies including 1751 patients (figure 01.03). First-line administration of purine antagonists resulted in a significantly higher rate of complete responses compared to therapy with alkylators (RR 1.94; 95% CI 1.65 to 2.28; P &lt; 0.00001). Given an estimated a complete response rate of 20% with alkylator-based treatment (range 4 to 37%), six patients would have to be treated with purine antagonists to achieve one additional complete response (NNT = 5.5; 95% CI 4.5 to 7.7). No publication bias was detectable on funnel plots and in the linear regression test (P = 0.4), but again we observed statistically significant heterogeneity (P = 0.0009). In parallel to the meta-analysis on overall responses, sensitivity analyses on study quality and type of purine antagonist administered were performed. Accordingly, the observed heterogeneity for the estimated treatment effect on achieving complete responses may at least in part be attributable to study quality (P = 0.05, figure 01.10) and the use of cladribine (P = 0.002, figure 01.12). Only two trials including 1275 patients reported the rates of complete responses according to the stage of disease (figure 01.14). Treatment with purine antagonists resulted in significantly higher rates of complete responses in both high-risk (RR 1.76; 95% CI 1.12 to 2.52) and low-risk patients (RR 1.94; 95% CI 1.55 to 2.43). No heterogeneity between subgroups was detectable (P = 0.60).</P>
<P>
<B>Progression-free survival</B>
<BR/>Data on progression-free survival were available for 4 studies including 1638 patients (figure 01.04). Treatment with purine antagonists was associated with a statistically significant longer time to progression compared to alkylator therapy (HR 0.70; 95% CI 0.61 to 0.82; P &lt; 0.00001). However, funnel plot and linear regression test suggest the presence of publication bias (P = 0.025). Furthermore, heterogeneity among the treatment effects was also statistically significant (P = 0.01). As shown in figure 1.2, definitions of "time to progression" varied greatly. In the absence of individual patient data we calculated progression-free survival according to tabulated data given in the original publications, which may explain the heterogeneity observed concerning this endpoint.</P>
<P>
<B>Haemolytic anaemia</B>
<BR/>Data on the occurrence of haemolytic anaemia were given in three studies including 1258 patients (figure 01.06) . Although none of the original trials described a statistically significant increase in haemolytic anaemia, we found that treatment with purine antagonists significantly increases the risk for developing this complication compared to alkylator-based regimens (RR 3.36; 95% CI 1.27 to 8.91; P = 0.01). However, due to the very low incidence of haemolytic anaemia in the study population (range: 1 to 4%) calculation of NNH was omitted.</P>
<P>
<B>Neutropenia and infections (Grade III to IV</B>)<BR/>Complete data on infectious adverse events and neutropenia were available for four studies including 1620 patients (figure 01.07 and figure 01.08). None of the studies recommended the prophylactic administration of antibiotics and/or granulocyte-stimulating factor. No data were available for the study reported by Spriano and co-workers. No significant difference was detectable concerning the observed rates of grade III/IV neutropenia (RR 1.14; 95% CI 0.98 to 1.34). However, with the use of purine antagonists significantly more grade III/IV infections occurred compared to alkylator-based treatment regimens (RR 1.86; 95% CI 1.28 to 2.71). Based on an estimated rate of about 6% in the control group, this means 20 patients need to be treated with purine antagonists for one additional patient to be harmed by severe infection (i.e., grade III to IV) compared to alkylator therapy (NNH = 20.0; 95% CI 12.50 to 50.0). Regarding these endpoints, there was no evidence for heterogeneity between the various trials (P = 0.21 and P = 0.34, respectively).</P>
<P>
<B>Therapy-related mortality</B>
<BR/>Data on therapy-related mortality as assessed by the treating trial physicians were available for four trials including 1630 patients (figure 01.05). Overall, incidence of treatment-related mortality was low (range: 0.2 to 2.8%) and equally distributed between both treatment modalities (RR 0.94; 95% CI 0.45 to 1.95).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-05 15:29:36 +0100" MODIFIED_BY="Nicole Skoetz">
<P>Neither the institution of treatment in early stages nor the substitution of chlorambucil by CVP or CHOP led to an improvement of overall survival in patients with B-CLL (<LINK REF="REF-CLL-Trialists_x0027_-Group" TYPE="REFERENCE">CLL Trialists' Group</LINK>). However, there is indirect evidence from epidemiologic data suggesting an improved 5 year survival rate for B-CLL patients treated between 1987 and 1989 compared to those treated between 1978 and 1981 (<LINK REF="REF-Carli-1998" TYPE="REFERENCE">Carli 1998</LINK>). Furthermore, Molica and coworkers presented stage-adjusted survival data indicating that patients who were diagnosed as having Binet C disease between 1991 and 1998 had a significantly longer survival than those diagnosed between 1970 and 1979 (<LINK REF="REF-Molica-2001" TYPE="REFERENCE">Molica 2001</LINK>). Such data are difficult to interpret and prone to bias but this improvement might be at least in part due to the introduction of more effective therapeutics such as purine antagonists into the treatment of B-CLL.<BR/>Despite the rather longer period of time elapsed since the publication of the first clinical trials involving fludarabine in 1989, we were able to find only nine randomised clinical trials comparing purine antagonists with alkylator-based regimens. Of those, just four have been published in peer-reviewed journals (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>; <LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>; <LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>; <LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). Three additional trials,i.e., German <LINK REF="STD-CLL5" TYPE="STUDY">CLL5</LINK> trial (<LINK REF="STD-CLL5" TYPE="STUDY">CLL5</LINK>), MRC-CLL4 trial (<LINK REF="STD-MRC-CLL4" TYPE="STUDY">MRC CLL4</LINK>), and International Phase III trial on B-CLL (<LINK REF="STD-Int.-Phase-III-trial" TYPE="STUDY">Int. Phase III trial</LINK>) stopped recruitment only recently and as they have not been fully evaluated yet they were excluded from this study. With a large amount of data from these important trials on efficacy, safety, and survival with purine antagonist monotherapy still pending, ongoing trials now use purine antagonists in conjunction with other cytotoxics and/or monoclonal antibodies. In view of this rapidly progressing trial activity it is acceptable to perform a systematic review on trials comparing single-agent purine antagonists with alkylator-based therapy and meta-analyse the data presently available. Data from this analysis might not only be important to draw firm conclusions for management of B-CLL in everyday clinical practice but also for the conduct of CLL trials in general.<BR/>The primary findings of this study are as follows: </P>
<OL>
<LI>Although results are suggestive that first-line treatment with purine antagonists may improve overall survival compared to alkylator-based therapy, there is currently insufficient statistical evidence to confirm this hypothesis. </LI>
<LI>Purine antagonists significantly improve overall and complete response rates and produce longer remission duration. There is, however, significant heterogeneity between trials which might be largely or wholly due to differences between study designs with respect to response evaluation. </LI>
<LI>There is strong statistical evidence that treatment with purine antagonists results in more clinically relevant infections, however there was no evidence for an impact on treatment-related mortality. </LI>
<LI>Treatment with purine antagonists given as a single-agent significantly increases the risk for developing haemolytic anaemia.</LI>
</OL>
<P>Formally, the five trials including 1838 randomised patients displayed marked differences in sample size (range 88-938 patients) and in particular concerning the number of patients recruited per participating center. For example, both the trials reported by Johnson et al. (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>) and Rai et al. (<LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>) recruited on average one patient per center and year, whereas the study reported by Robak et al. recruited on average six patients per year and center (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). Given a prevalence of 50,000 to 60,000 CLL patients in the United States alone (<LINK REF="REF-SEER-database" TYPE="REFERENCE">SEER database</LINK>) we cannot exclude the possibility of a highly selected study population in some of the trials which may limit the generalisability of the respective results. Since the majority of CLL patients are of advanced age and often suffer from substantial co-morbidities, conclusions drawn from such selected patient cohorts have to be handled with caution when translated into everyday clinical practice. Furthermore, inclusion criteria concerning age, stage, the requirement and definition of active disease varied substantially and we have no information on the distribution of powerful prognostic markers such as cytogenetics, ZAP-70, CD38 and mutational status of the immunoglobulin variable chain gene, that have been described only recently (<LINK REF="REF-Dohner-2000" TYPE="REFERENCE">Dohner 2000</LINK>; <LINK REF="REF-Crespo-2003" TYPE="REFERENCE">Crespo 2003</LINK>; <LINK REF="REF-Damle-1999" TYPE="REFERENCE">Damle 1999</LINK>; <LINK REF="REF-Hamblin-2002" TYPE="REFERENCE">Hamblin 2002</LINK>). While heterogenous distribution of these parameters and the different inclusion criteria applied might influence efficacy of treatment, differences in exclusion criteria might impact on the occurrence of adverse effects. Preselection of study participants concerning age, performance status, presence of a positive Coombs test or overt autoimmune haemolytic anaemia and varying definitions of impaired renal or liver function parameters as observed in the included trials might explain the differences concerning number and extent of side effects observed in the individual trials.<BR/>Concerning the primary endpoint of this meta-analysis, i.e. overall survival, we failed to demonstrate that treatment with purine antagonists produces a significant survival advantage for patients with previously untreated B-CLL as compared to alkylator-based regimens. However, we found a trend towards increased overall survival for patients receiving purine antagonists and greater statistical power to establish whether there is a real survival advantage or not will be achieved by the inclusion of the three yet unpublished trials including over 1,100 randomised patients, which is due in an update of this systematic review. There are, however, potential pitfalls when meta-analysing tabulated survival data in this setting. The four trials for whom survival data were available (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>; <LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>; <LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>; <LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>) had a cross-over design using different options ranging from possible to mandatory crossing-over and only one study defined re-treatment modalities in detail. Heterogeneity in crossing-over options and different re-treatment strategies may therefore interfere with survival analysis and we strongly suggest to include specific re-treatment strategies into future study protocols.</P>
<P>Concerning treatment efficacy we detected a statistically significant improved overall response rate and also significantly more complete remissions among patients receiving purine antagonists. This treatment effect remained robust in subgroup analyses according to stage, type of purine antagonist administered and different comparators, i.e., CAP, CHOP or chlorambucil. Moreover, this benefit appears to be more pronounced in advanced stages (RR 1.40; 95% CI 1.19 to 1.65) compared to low and intermediate stages (RR 1.19; 95% CI 1.10 to 1.29). However, there is a substantial degree of heterogeneity which is neither attributable to varying study quality nor publication bias. Subgroup analysis concerning the type of purine antagonist administered indirectly suggests a superiority of cladribine over fludarabine, but cladribine was applied in only one trial. In the absence of a direct comparative trial, there is, currently no good evidence from the literature that cladribine is superior to fludarabine in terms of improved response rates (<LINK REF="REF-Nabhan-2004" TYPE="REFERENCE">Nabhan 2004</LINK>). There are other profound differences in trial design that may cause heterogeneity. Besides different study endpoints (overall survival vs progression-free survival vs response rate), we observed markedly divergent study designs in terms of minimum and maximum duration of treatment, time points for re-staging and staging criteria applied. Apparently, such differences in dose intensity and cumulative drug dosage can impact on tumour biology and development of drug resistance (<LINK REF="REF-Panasci-2001" TYPE="REFERENCE">Panasci 2001</LINK>). Moreover, dosages of chlorambucil used in the comparator arm varied greatly ranging from 40 mg/m<SUP>2</SUP> per month (<LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>) to 84 mg/m<SUP>2</SUP> per month (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). Given a dose-response relationship for chlorambucil as anticipated by some authors , heterogeneity concerning the relative risk for obtaining a response with purine antagonists must be anticipated (<LINK REF="REF-Jaksic-1997" TYPE="REFERENCE">Jaksic 1997</LINK>; <LINK REF="REF-Summerfield-2002" TYPE="REFERENCE">Summerfield 2002</LINK>). Finally, the currently applied response evaluation system represents another potential source of heterogeneity between CLL trials. In four trials (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>; <LINK REF="STD-Rai-2000" TYPE="STUDY">Rai 2000</LINK>; <LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>; <LINK REF="STD-Spriano-1999" TYPE="STUDY">Spriano 1999</LINK>) clinical response evaluation was performed according to the NCI criteria of 1988. One trial (<LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>) stated to apply NCI criteria of 1996, which recommend the application of ultrasound or computed tomography in addition to clinical assessment of the spleen and lymph nodes as required for the criteria of 1988 (<LINK REF="REF-Cheson-1996" TYPE="REFERENCE">Cheson 1996</LINK>). In the original report of the publication, however, the authors state explicitly that imaging studies were not used for assessment of response. In other words, if a patient has nodal disease progression in anatomic areas not accessible for clinical examination, e.g., the abdomen, he still may be evaluated as a complete remission. In order to demonstrate and depict the possible consequences of different staging systems we subsequently carried out a response evaluation with and without imaging studies within the same patient sample (N = 80) who had received treatment with fludarabine for symptomatic B-CLL during a phase II trial (Greil et al., manuscript in preparation). While clinical staging through physical examination as required by the NCI criteria of 1988 revealed pathological spleen size in 26 % of patients, ultrasound studies revealed splenomegaly in 78% of cases.<BR/>Progression-free survival is an important endpoint in many cancer subtypes, particularly in those with a chronic and symptomatic clinical course. Irrespective of the different definitions applied in the individual trials, patients treated with purine antagonists had a significantly prolonged progression-free survival, time to re-treatment and event-free survival, respectively. Of note, differences observed between purine antagonists and alkylator-based therapy were in the range of 3 to over 18 months, pointing to profound heterogeneity in patient selection, trial design and definition of parameters. In fact, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> depicts the different definitions of progression-free interval, progression-free survival, event-free survival and time to progression used in the various trials. Where the definition of progression includes change of treatment, this may lead to bias in the comparisons between treatments. The diverse definitions for measuring survival without disease progression are easily confounded and may indeed be misleading: Applying the different definitions to our phase II study cohort described above, the pure difference in progression-free resulting from definition (and not from treatment effect) may be as high as 17 months (Greil et al., manuscript in preparation). It is therefore one of the most important findings of this survey, that future clinical trials in B-CLL need harmonization of relevant and obligatory primary endpoints, their exact definition and principle framework concerning trial design which allow a meaningful comparison of trials. Furthermore, there is an urgent need for more stringent response definitions, with validation of their reproducibility and clinical use. Despite the heterogeneity it is, however, acceptable to perform a meta analysis in our setting since the comparison is always within trial, so like is being compared with like.</P>
<P>Concerning side effects, we found that purine antagonists caused slightly more grade III/IV neutropenia, however this effect did not reach statistical significance. Notably, significantly more episodes of severe infections (grade III/IV) occurred in patients undergoing treatment with purine antagonists compared to alkylators (RR = 1.97; 95%CI 1.33 to 2.99). In addition, the number of haemolytic anemias increased significantly, i.e. nearly tripled, with occasionally fatal course (<LINK REF="STD-FCG-on-CLL-1996" TYPE="STUDY">FCG on CLL 1996</LINK>; <LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). The overall number of haemolytic anemias reported during therapy was, however, very low with 20 cases among 1258 patients (1.6%). This significantly increased treatment-associated toxicity had no impact on the number of treatment-related deaths as assessed by the individual investigators. However there is need for words of caution. Patients included may have been at low risk because of exclusion criteria such as positive direct Coombs test. The proportion of patients reported to have experienced at least one episode of grade III/IV infection with purine antagonist therapy varied greatly between 6.7% in the trial reported by Leporrier et al. (<LINK REF="STD-Leporrier-2001" TYPE="STUDY">Leporrier 2001</LINK>) and 19.8% in the study by Robak and coworkers (<LINK REF="STD-Robak-2000" TYPE="STUDY">Robak 2000</LINK>). Indeed, cladribine may be more myelosuppressive than fludarabine (<LINK REF="REF-Robak-2002" TYPE="REFERENCE">Robak 2002</LINK>; <LINK REF="REF-Tondini-2000" TYPE="REFERENCE">Tondini 2000</LINK>) and this group used prednisone in addition to cladribine and chlorambucil, respectively. Combination of steroids and purine antagonists is known to cause an increased rate of opportunistic infections and therefore is usually not recommended (<LINK REF="REF-Robak-2002" TYPE="REFERENCE">Robak 2002</LINK>; <LINK REF="REF-Anaissie-1998" TYPE="REFERENCE">Anaissie 1998</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-05 15:29:52 +0100" MODIFIED_BY="Nicole Skoetz">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-05 15:29:52 +0100" MODIFIED_BY="Nicole Skoetz">
<P>There is strong evidence that first-line treatment with purine antagonists is more effective in terms of achieving a response compared to alkylator-based therapy. Notably, patients are more likely to obtain a complete response. Survival without disease progression after having undergone treatment with purine antagonists is longer compared to progression-free survival after alkylator therapy. There is, however, insufficient evidence to determine whether these effects translate into longer overall survival. Due to significantly more toxicity in terms of severe infections and potentially dangerous autoimmune haemolytic anaemia we therefore recommend to use purine antagonists after careful consideration of the patient's performance status, age and co-morbidities.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future trials should include quality of life measures, which may be particularly important in situations where response rates are improved but not survival. This review suffers from the great heterogeneity concerning study conduct, definition of study parameters and interpretation of response criteria. We therefore strongly suggest to establish an international consensus on precise definitions of study parameters and guidelines concerning the conduct of studies in B-CLL in general. Furthermore, a meta-analysis using individual patient data might be able to overcome some of the difficulties resulting from heterogeneity. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the corresponding authors of the original studies, especially Dr. Robak with co-workers, Drs. Rai, Larson and Peterson from CALGB (National Cancer Institute grant number CA 31946) and Dr. Therese Lackner-Matula from Schering AG for providing additional study data. We would also like to thank the editors and members of the editorial base of the Cochrane Haematological Malignancies Group (Cologne, Germany) for technical and scientific advice, critical review of the study proposal and final draft. The CHMG is funded by the German Ministry of Education and Research (BMBF).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>R.G. is principal investigator of two investigator-initiated trials including fludarabine and is receiving support for these trials from Schering AG.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>MICHAEL STEURER: Coordinating the review, protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting of final review</P>
<P>GEORG PALL: Protocol development, searching for trials, eligibility and quality assessment, data extraction and analysis, drafting of final review</P>
<P>SUE RICHARDS: Protocol development, providing general advice on the review</P>
<P>GUIDO SCHWARZER: Data management, statistical analysis, extraction of time-to-event data</P>
<P>JULIA BOHLIUS: Protocol development, providing general advice on the review</P>
<P>RICHARD GREIL: Protocol development, providing general advice on the review, drafting of final review, securing funding<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-FCG-on-CLL-1996" NAME="FCG on CLL 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;UI - 96225350&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The French Cooperative Group on CLL, Johnson S, Smith AG, Löffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W</AU>
<TI>Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>9013</NO>
<PG>1432-38</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8676625"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leporrier-2001" NAME="Leporrier 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;UI - 21471953&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C</AU>
<TI>Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients</TI>
<SO>Blood</SO>
<YR>2001</YR>
<VL>98</VL>
<NO>8</NO>
<PG>2319-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11588025"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rai-2000" NAME="Rai 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;UI - 20550367&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA</AU>
<TI>Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>24</NO>
<PG>1750-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11114313"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Robak-2000" NAME="Robak 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;DA - 20001109&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robak T, Blonski JZ, Kasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszynska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P</AU>
<TI>Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>8</NO>
<PG>2723-2729</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11023504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spriano-1999" NAME="Spriano 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Spriano M, Chiurazzi F, Liso V, Mazza P, Molica S, Gobbi M</AU>
<TI>Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL</TI>
<SO>Hematology and Cell Therapy</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>1</NO>
<PG>93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11036943"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaksic-2000" NAME="Jaksic 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jaksic B, Brugiatelli M, Suciu S, Beaumelou E, Wijermans PW, Delmer A, Roozendaal KJ, Teixeira A, Jehn U, Feremans W, Belhabri A, Egyed M, Venditi A, Indrak K, Cevreska L, Rodts P, Solbu G, Willemze R, De Witte TM, and for EORTC Leukemia Group</AU>
<TI>Fludarabine vs high-dose chlorambucil in advanced B-cell chronic lymphocytic leukemia (B-CLL): Results of EORTC phase-II randomized trial after 4 years of median follow-up.</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>758a</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11109927"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-CLL5" NAME="CLL5" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Int.-Phase-III-trial" NAME="Int. Phase III trial" YEAR="">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-MRC-CLL4" NAME="MRC CLL4" YEAR="">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Anaissie-1998" NAME="Anaissie 1998" NOTES="&lt;p&gt;DA - 19981001&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ</AU>
<TI>Infections in patients with chronic lymphocytic leukemia treated with fludarabine</TI>
<SO>Ann Intern Med</SO>
<YR>1998</YR>
<VL>129</VL>
<NO>7</NO>
<PG>559-566</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9758577"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Binet-1981" NAME="Binet 1981" NOTES="&lt;p&gt;UI - 81209824&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F</AU>
<TI>A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>48</VL>
<NO>1</NO>
<PG>198-206</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7237385"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carli-1998" NAME="Carli 1998" NOTES="&lt;p&gt;DA - 19990311&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Carli PM, Coebergh JW, Verdecchia A</AU>
<TI>Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group</TI>
<SO>Eur J Cancer</SO>
<YR>1998</YR>
<VL>34</VL>
<NO>14</NO>
<PG>2253-2263</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10773535"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cartwright-1990" NAME="Cartwright 1990" TYPE="BOOK_SECTION">
<AU>Cartwright RA, Alexander FE, McKinney PA, Rickets TJ</AU>
<TI>Leukemia and Lymphoma: An atlas of distribution within areas of England and Wales 1984-88</TI>
<SO>Leukaemia Research Fund</SO>
<YR>1990</YR>
<PB>Leukemia Research Fund</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCO-2002" NAME="CCO 2002" TYPE="OTHER">
<AU>Chin Yee I, Makarski J, Browman G, Wong S, Esmail R, Meyer R and The Hematology Disease Site Group (Cancer Care Ontario)</AU>
<TI>Fludarabine in intermediate- and high-risk chronic lymphocytic leukemia</TI>
<SO>www.ccopebc.ca/guidelines/hem/cpg6_1f.html</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheson-1988" NAME="Cheson 1988" NOTES="&lt;p&gt;UI - 89047387&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ</AU>
<TI>Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group</TI>
<SO>American Journal of Hematology</SO>
<YR>1988</YR>
<VL>29</VL>
<NO>3</NO>
<PG>152-163</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3189311"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cheson-1996" NAME="Cheson 1996" NOTES="&lt;p&gt;UI - 96247500&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR</AU>
<TI>National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>87</VL>
<NO>12</NO>
<PG>4990-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8652811"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CLL-Trialists_x0027_-Group" NAME="CLL Trialists' Group" NOTES="&lt;p&gt;UI - 99270754&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>CLL Trialists´ Collaborative Group</AU>
<TI>Chemotherapeutic options in chronic lymphocytic leukemia: a meta- analysis of the randomized trials. CLL Trialists' Collaborative Group</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>19-5-1999</YR>
<VL>91</VL>
<NO>10</NO>
<PG>861-868</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10340906"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crespo-2003" NAME="Crespo 2003" NOTES="&lt;p&gt;DA - 20030501&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E</AU>
<TI>ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia</TI>
<SO>N Engl J Med</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>18</NO>
<PG>1764-1775</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12724482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Damle-1999" NAME="Damle 1999" NOTES="&lt;p&gt;DA - 19991012&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N</AU>
<TI>Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia</TI>
<SO>Blood</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>6</NO>
<PG>1840-1847</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10477721"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dohner-2000" NAME="Dohner 2000" NOTES="&lt;p&gt;DA - 20001220&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P</AU>
<TI>Genomic aberrations and survival in chronic lymphocytic leukemia</TI>
<SO>N Engl J Med</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>26</NO>
<PG>1910-1916</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11136261"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" NOTES="&lt;p&gt;UI - 98092060&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Phillips AN</AU>
<TI>Meta-analysis: principles and procedures</TI>
<SO>British Medical Journal</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7121</NO>
<PG>1533-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9432252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FCG-on-CLL-1990" NAME="FCG on CLL 1990" NOTES="&lt;p&gt;UI - 90199061&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>The French Cooperative Group on Chronic Lymphocytic Leukemia</AU>
<TI>A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia</TI>
<SO>Blood</SO>
<YR>1990</YR>
<VL>75</VL>
<NO>7</NO>
<PG>1422-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2180493"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hamblin-2002" NAME="Hamblin 2002" NOTES="&lt;p&gt;DA - 20020124&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG</AU>
<TI>CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>3</NO>
<PG>1023-1029</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11807008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ihaka-1996" NAME="Ihaka 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ihaka R, Gentleman R</AU>
<TI>R: A Language for Data Analysis and Graphics</TI>
<SO>Journal of Computational and Graphical Statistics</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>3</NO>
<PG>299-314</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="http://search.epnet.com/direct.asp?an=9609114569&amp;amp;db=bsh"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jaksic-1997" NAME="Jaksic 1997" NOTES="&lt;p&gt;DA - 19970703&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Planinc-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D</AU>
<TI>High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna</TI>
<SO>Cancer</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>11</NO>
<PG>2107-2114</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9179056"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keating-1989" NAME="Keating 1989" NOTES="&lt;p&gt;UI - 89323335&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB</AU>
<TI>Fludarabine: a new agent with major activity against chronic lymphocytic leukemia</TI>
<SO>Blood</SO>
<YR>1989</YR>
<VL>74</VL>
<NO>1</NO>
<PG>19-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2473795"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kimby-2001" NAME="Kimby 2001" NOTES="&lt;p&gt;UI - 21334922&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kimby E, Brandt L, Nygren P, Glimelius B</AU>
<TI>A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia</TI>
<SO>Acta Oncologica</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>2-3</NO>
<PG>224-230</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11441934"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kipps-1995" NAME="Kipps 1995" TYPE="BOOK_SECTION">
<AU>Kipps TJ</AU>
<TI>Chronic lymphocytic leukemia and related diseases</TI>
<SO>William´s Hematology</SO>
<YR>1995</YR>
<PG>1017</PG>
<PB>McGraw-Hill Education (ISE Editions)</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levy-2001" NAME="Levy 2001" NOTES="&lt;p&gt;DA - 20010704&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S</AU>
<TI>Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis</TI>
<SO>J Clin Epidemiol</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>7</NO>
<PG>747-754</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11438417"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Molica-2001" NAME="Molica 2001" NOTES="&lt;p&gt;DA - 20010126&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Molica S, Levato D</AU>
<TI>What is changing in the natural history of chronic lymphocytic leukemia?</TI>
<SO>Haematologica</SO>
<YR>2001</YR>
<VL>86</VL>
<NO>1</NO>
<PG>8-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11146563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nabhan-2004" NAME="Nabhan 2004" NOTES="&lt;p&gt;DA - 20040407&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Nabhan C, Gartenhaus RB, Tallman MS</AU>
<TI>Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era</TI>
<SO>Leuk Res</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>5</NO>
<PG>429-442</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15068894"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Panasci-2001" NAME="Panasci 2001" NOTES="&lt;p&gt;DA - 20010411&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R</AU>
<TI>Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair</TI>
<SO>Clin Cancer Res</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>3</NO>
<PG>454-461</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11297233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" NAME="Parmar 1998" NOTES="&lt;p&gt;UI - 99120172&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9921604"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rai-1975" NAME="Rai 1975" NOTES="&lt;p&gt;UI - 75184472&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS</AU>
<TI>Clinical staging of chronic lymphocytic leukemia</TI>
<SO>Blood</SO>
<YR>1975</YR>
<VL>46</VL>
<NO>2</NO>
<PG>219-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1139039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Robak-2002" NAME="Robak 2002" NOTES="&lt;p&gt;DA - 20020531&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Robak T, Kasznicki M</AU>
<TI>Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia</TI>
<SO>Leukemia</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1015-1027</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12040433"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rozman-1995" NAME="Rozman 1995" NOTES="&lt;p&gt;UI - 95405434&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rozman C, Montserrat E</AU>
<TI>Chronic lymphocytic leukemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>16</NO>
<PG>1052-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7675049"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SEER-database" NAME="SEER database" TYPE="COMPUTER_PROGRAM">
<TI>Surveillance, Epidemiology, and End Results (SEER) Programm</TI>
<YR>2004</YR>
<PB>National Cancer Institute</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Summerfield-2002" NAME="Summerfield 2002" NOTES="&lt;p&gt;DA - 20020311&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Summerfield GP, Taylor PR, Mounter PJ, Proctor SJ</AU>
<TI>High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma</TI>
<SO>Br J Haematol</SO>
<YR>2002</YR>
<VL>116</VL>
<NO>4</NO>
<PG>781-786</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11886381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tondini-2000" NAME="Tondini 2000" NOTES="&lt;p&gt;DA - 20000621&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tondini C, Balzarotti M, Rampinelli I, Valagussa P, Luoni M, De Paoli A, Santoro A, Bonadonna G</AU>
<TI>Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study</TI>
<SO>Ann Oncol</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>2</NO>
<PG>231-233</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10761763"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-05 15:30:36 +0100" MODIFIED_BY="Nicole Skoetz">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-FCG-on-CLL-1996">
<CHAR_METHODS>
<P>RCT <BR/>5/90 - 7/92</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>B-CLL<BR/>Symptomatic Binet B or Binet C<BR/>&gt;18 years<BR/>N = 105</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 iv d1-5;<BR/>q 4 weeks<BR/>vs<BR/>CAP:<BR/>Cyclophosphamide 750mg/m2 iv d1,<BR/>Doxorubicin 50mg/m2 iv d1,<BR/>Prednisone 40mg/m2 po d1-5;<BR/>q 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response Rates<BR/>Side-Effects<BR/>Progression-free Intervals<BR/>Overall Survival<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>only previously untreated patients were included; additional data was obtained from sponsor</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Leporrier-2001">
<CHAR_METHODS>
<P>RCT<BR/>6/90 - 4/98</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>B-CLL<BR/>Binet B/C<BR/>&lt;75 years<BR/>N = 938</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 iv d1-5;<BR/>q 4 weeks <BR/>vs.<BR/>CHOP:<BR/>Cyclophosphamide 300mg/m2 po d1-5,<BR/>Doxorubicin 25mg/m2 iv d1,<BR/>Vincristine 1mg/m2 iv d1,<BR/>Prednisone 40mg/m2 po d1-5;<BR/>q 4 weeks <BR/>vs.<BR/>CAP:<BR/>as reported by the FCG 1996</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall Survival<BR/>Response Rates<BR/>Time To Progression<BR/>Time To Retreatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>CAP arm was closed prematurely after interim analysis due to reduced response rates</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Rai-2000">
<CHAR_METHODS>
<P>RCT<BR/>10/90 - 12/94</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>B-CLL<BR/>Rai III/IV<BR/>Symptomatic Rai I/II<BR/>&gt;18 years<BR/>N = 395<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 iv d1-5;<BR/>q 4 weeks<BR/>vs.<BR/>Chlorambucil 40mg/m2 po d1;<BR/>q 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Progression Free Survival*<BR/>Response Rates<BR/>Duration Of Response<BR/>Time To Progression<BR/>Overall Survival<BR/>Side Effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Primary endpoint changed during the study: Complete response was substituted by Progression free survival<BR/>additional study data was obtained from authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Robak-2000">
<CHAR_METHODS>
<P>RCT<BR/>05/95 - 05/98</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>B-CLL<BR/>Rai III/IV<BR/>Symptomatic Rai 0 - II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2-CdA 0,12mg/kg iv d1-5<BR/>Prednisone 30mg/m2 po d1-5<BR/>q 4 weeks<BR/>vs.<BR/>Chlorambucil 12mg/m2 po d1-7<BR/>Prednisone 30mg/m2 po d1-7<BR/>q 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response Rates<BR/>Overall Survival<BR/>Progression Free Survival<BR/>Event Free Survival<BR/>Drug Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-Spriano-1999">
<CHAR_METHODS>
<P>RCT<BR/>8/94 - end of recruitment period not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-05 15:00:09 +0100" MODIFIED_BY="Nicole Skoetz">
<P>B-CLL<BR/>Rai II-IV<BR/>N = 150<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 iv d1-5;<BR/>q 4 weeks<BR/>vs.<BR/>Chlorambucil 30mg/m2 po d1,15<BR/>Prednisone 40mg/m2 i.m. d1-5,d15-19;<BR/>q 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Response Rates<BR/>Response Duration<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>no additional study data was available from authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Jaksic-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised data included in published analysis. Authors did not respond to repeated data clarification requests.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-05 15:30:36 +0100" MODIFIED_BY="Nicole Skoetz" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2008-11-05 15:30:36 +0100" MODIFIED_BY="Nicole Skoetz" STUDY_ID="STD-CLL5">
<CHAR_STUDY_NAME>
<P>CLL5, German CLL Study Group</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2008-11-05 15:30:36 +0100" MODIFIED_BY="Nicole Skoetz">
<P>patients over 65 years of age with previously untreated B-CLL in stage Binet C or stages A or B when requiring treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 d 1-5 q28d; maximum of 6 cycles<BR/>vs.<BR/>chlorambucil 0.4 - 0.8 mg/kg/d d1+15 until maximum response is reached (maximum 1 year)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>overall survival, remission rates, remission duration, toxicity, quality of life, life-threatening infections</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>08/1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>German CLL Study Group</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>trial closed 09/2004</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Int.-Phase-III-trial">
<CHAR_STUDY_NAME>
<P>International Phase III trial on B-CLL</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>B-CLL, Binet stage B or C, or progressive symptomatic stage A , in need of systemic therapy , Life expectancy &gt;6 months with therapy. <BR/>Age 18-75 years. <BR/>Informed consent according to the requirements of the local ethics committee. <BR/>No previous chemotherapy or cytotoxic immune therapy (restricted field radiotherapy, splenectomy, biological response modifiers and oral prednisone allowed). <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 iv d 1-5 or 40mg/m2 po d 1-5 q28d for up to 6 courses<BR/>vs.<BR/>cladribine 5mg/m2 sq or iv d 1-5 q28d<BR/>or cladribine 10mg/m2 po d 1-5<BR/>vs.<BR/>chlorambucil 10mg/m2 po d 1-10 q28d up to 6 courses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Overall response,<BR/>overall survival, progression-free survival, complete response rate.<BR/>toxicity, quality-of-Life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>11/1997</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>www.cck.ki.se/CLL-study/index.html</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>trial closed 10/2004</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-MRC-CLL4">
<CHAR_STUDY_NAME>
<P>MRC CLL4 trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>previously untreated B-CLL stage Binet A progressive or stage B or stage C</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Fludarabine 25mg/m2 iv or 40mg/m2 po d 1-5 q28d 3-6 for cycles<BR/>vs.<BR/>chlorambucil 10mg/m2 po d 1-7 q 28d until maximum response or up to 1 year<BR/>vs<BR/>Fludarabine 25mg/m2 iv d 1-3 or 24mg/m2 po d 1-5 in combination with cyclophosphamide 250mg/m2 iv d 1-3 or 150mg/m2 po d 1-5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>survival, tumor response, toxicity, quality of life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>03/1999</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>UK Medical Research Council</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>trial closed 10/2004</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-FCG-on-CLL-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Leporrier-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rai-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Robak-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Spriano-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-05 15:31:01 +0100" MODIFIED_BY="Nicole Skoetz">
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Quality assessment</TITLE>
<TABLE COLS="9" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Random allocation</P>
</TH>
<TH>
<P>Allocation concealed</P>
</TH>
<TH>
<P>Completeness</P>
</TH>
<TH>
<P>ITT analysis</P>
</TH>
<TH>
<P>Retreatment strategy</P>
</TH>
<TH>
<P>Response criteria</P>
</TH>
<TH>
<P>Publication type</P>
</TH>
<TH>
<P>Similarity of groups</P>
</TH>
</TR>
<TR>
<TD>
<P>FCG on CLL 1996</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not defined</P>
</TD>
<TD>
<P>yes, 1988</P>
</TD>
<TD>
<P>peer-reviewed journal</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Rai 2000</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not defined</P>
</TD>
<TD>
<P>yes, 1988</P>
</TD>
<TD>
<P>peer-reviewed journal</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Robak 2000</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes, 1988</P>
</TD>
<TD>
<P>peer-reviewed journal</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Leporrier 2001</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>not defined</P>
</TD>
<TD>
<P>yes, 1996</P>
</TD>
<TD>
<P>peer-reviewed journal</P>
</TD>
<TD>
<P>yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Spriano 1999</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>unclear</P>
</TD>
<TD>
<P>abstract</P>
</TD>
<TD>
<P>unclear</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Patients' characteristics</TITLE>
<TABLE COLS="6" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Median Age (range)</P>
</TH>
<TH>
<P>Stage</P>
</TH>
<TH>
<P>Median WBC (range)</P>
</TH>
<TH>
<P>Median Hb (range)</P>
</TH>
<TH>
<P>Median Plt (range)</P>
</TH>
</TR>
<TR>
<TD>
<P>FCG on CLL 1996</P>
</TD>
<TD>
<P>62.5 (39 - 79)</P>
</TD>
<TD>
<P>Binet B 64%, Binet C 36%</P>
</TD>
<TD>
<P>101.4 G/L (5.6 - 999)</P>
</TD>
<TD>
<P>11.7 g/dL (5.7 - 16.2)</P>
</TD>
<TD>
<P>172,000/µL (1000 - 405,000)</P>
</TD>
</TR>
<TR>
<TD>
<P>Leporrier 2001</P>
</TD>
<TD>
<P>63 (53 - 71)</P>
</TD>
<TD>
<P>Binet B 69.5%, Binet C 30.5%</P>
</TD>
<TD>
<P>lymphocyte count: 55.7 G/L (19 - 194)</P>
</TD>
<TD>
<P>11.4 g/dL (7.7 - 14.5)</P>
</TD>
<TD>
<P>135,000/µL (88,000 - 228,000)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rai 2000</P>
</TD>
<TD>
<P>63 (33 - 89)</P>
</TD>
<TD>
<P>Rai I + II: 60%, Rai III + IV: 40%</P>
</TD>
<TD>
<P>81.4 G/L (8 - 709)</P>
</TD>
<TD>
<P>12.2 g/dL (5.3 - 16.7)</P>
</TD>
<TD>
<P>151,000/µL (10,000 - 451,000)</P>
</TD>
</TR>
<TR>
<TD>
<P>Robak 2000</P>
</TD>
<TD>
<P>61.5 (31 - 92)</P>
</TD>
<TD>
<P>Rai 0: 13.5%, Rai I + II: 53.5%, Rai III + IV: 33%</P>
</TD>
<TD>
<P>73.9 G/L (25.4 - 525)</P>
</TD>
<TD>
<P>12.5 g/dL (3.7 - 16.7)</P>
</TD>
<TD>
<P>146,800/µL (20,000 - 585,000)</P>
</TD>
</TR>
<TR>
<TD>
<P>Spriano 1999</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-11-05 15:31:01 +0100" MODIFIED_BY="Nicole Skoetz" NO="3">
<TITLE>General study data</TITLE>
<TABLE COLS="6" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Number of centers</P>
</TH>
<TH>
<P>Patients per center</P>
</TH>
<TH>
<P>Observation period</P>
</TH>
<TH>
<P>Exclusion criteria</P>
</TH>
<TH>
<P>Crossover modalities</P>
</TH>
</TR>
<TR>
<TD>
<P>FCG on CLL 1996</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>2.6</P>
</TD>
<TD>
<P>median: 34 months</P>
</TD>
<TD>
<P>Performance score WHO 4, Abnormal renal or liver function, uncontrolled AIHA and AITP, HIV-related disease, T-CLL, prolymphocytic leukaemia, Richter's syndrome</P>
</TD>
<TD>
<P>Possible in case of relapse after initial response</P>
</TD>
</TR>
<TR>
<TD>
<P>Leporrier 2001</P>
</TD>
<TD>
<P>73</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>median: 70 months</P>
</TD>
<TD>
<P>Concomitant neoplasms, AIHA, prolymphocytic leukaemia</P>
</TD>
<TD>
<P>Mandatory, if SD or PD after 3 cycles of fludarabine or CAP and after 6 cycles of CHOP, respectively</P>
</TD>
</TR>
<TR>
<TD>
<P>Rai 2000</P>
</TD>
<TD>
<P>127</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>median: 62 months</P>
</TD>
<TD>
<P>Performance score ECOG &gt;2, liver function parameters &gt; 1.5 upper normal limit, renal function parameters upper normal limit, positive Coombs test</P>
</TD>
<TD>
<P>Possible in case of PD or no response or in case of relapse within 6 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Robak 2000</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>median: 21 months</P>
</TD>
<TD>
<P>Performance status WHO 4, active infection, abnormal renal or liver function, Richter's syndrome</P>
</TD>
<TD>
<P>Mandatory in case of no response or PD after 3 cycles, or relapse within 12 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Spriano 1999</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" NO="4">
<TITLE>Overall survival: total number of deaths during treatment and follow-up</TITLE>
<TABLE COLS="5" ROWS="15">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Treatment arm</P>
</TH>
<TH>
<P>Patients assigned</P>
</TH>
<TH>
<P>Number of deaths</P>
</TH>
<TH>
<P>Observation period</P>
</TH>
</TR>
<TR>
<TD>
<P>FCG on CLL 1996</P>
</TD>
<TD>
<P>Fludarabine</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>18 (34%)</P>
</TD>
<TD>
<P>34 months</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>CAP</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>26 (50%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Leporrier 2001</P>
</TD>
<TD>
<P>Fludarabine</P>
</TD>
<TD>
<P>341</P>
</TD>
<TD>
<P>126 (37%)</P>
</TD>
<TD>
<P>70 months</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>CHOP, CAP</P>
</TD>
<TD>
<P>597</P>
</TD>
<TD>
<P>265 (44%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rai 2000</P>
</TD>
<TD>
<P>Fludarabine</P>
</TD>
<TD>
<P>195</P>
</TD>
<TD>
<P>84 (43%)</P>
</TD>
<TD>
<P>62 months</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Chlorambucil</P>
</TD>
<TD>
<P>200</P>
</TD>
<TD>
<P>110 (55%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Robak 2000</P>
</TD>
<TD>
<P>Cladribine (2-CdA)</P>
</TD>
<TD>
<P>133</P>
</TD>
<TD>
<P>25 (19%)</P>
</TD>
<TD>
<P>21 months</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Chlorambucil + Prednisone</P>
</TD>
<TD>
<P>117</P>
</TD>
<TD>
<P>17 (15%)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Spriano 1999</P>
</TD>
<TD>
<P>Fludarabine</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Chlorambucil</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Purine antagonists vs. alkylator-based regimens</NAME>
<IV_OUTCOME CHI2="3.6246810713026307" CI_END="1.0093185014569799" CI_START="0.778702118319761" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.8865429798627233" ESTIMABLE="YES" I2="17.234097538907996" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.004028234223249502" LOG_CI_START="-0.10862864388182566" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.05230020482928806" NO="1" P_CHI2="0.3049479627214303" P_Q="1.0" P_Z="0.06878940158910456" Q="0.0" RANDOM="NO" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="722" TOTAL_2="966" WEIGHT="100.0" Z="1.8198004342684602">
<NAME>Overall survival</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alkylators</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.0878329245705636" CI_START="0.28134106965285016" EFFECT_SIZE="0.5532197380808739" ESTIMABLE="YES" ESTIMATE="-0.592" LOG_CI_END="0.03656219912240015" LOG_CI_START="-0.5507668656958503" LOG_EFFECT_SIZE="-0.25710233328672505" ORDER="26796" SE="0.345" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" WEIGHT="3.679191880061294"/>
<IV_DATA CI_END="1.0780449460949881" CI_START="0.7918770290424666" EFFECT_SIZE="0.923947525072688" ESTIMABLE="YES" ESTIMATE="-0.0791" LOG_CI_END="0.03263686793246198" LOG_CI_START="-0.10134225496955643" LOG_EFFECT_SIZE="-0.0343526935185472" ORDER="26797" SE="0.0787" STUDY_ID="STD-Leporrier-2001" TOTAL_1="341" TOTAL_2="597" WEIGHT="70.70354078494329"/>
<IV_DATA CI_END="1.0462735104979106" CI_START="0.5949756409979663" EFFECT_SIZE="0.7889912880176098" ESTIMABLE="YES" ESTIMATE="-0.237" LOG_CI_END="0.01964523001186858" LOG_CI_START="-0.22550081443400993" LOG_EFFECT_SIZE="-0.10292779221107065" ORDER="26798" SE="0.144" STUDY_ID="STD-Rai-2000" TOTAL_1="195" TOTAL_2="200" WEIGHT="21.118625266410856"/>
<IV_DATA CI_END="2.1695261142556035" CI_START="0.638579715528403" EFFECT_SIZE="1.177036689688467" ESTIMABLE="YES" ESTIMATE="0.163" LOG_CI_END="0.33636488203326514" LOG_CI_START="-0.19478488093280502" LOG_EFFECT_SIZE="0.07079000055023003" ORDER="26799" SE="0.312" STUDY_ID="STD-Robak-2000" TOTAL_1="133" TOTAL_2="117" WEIGHT="4.4986420685845605"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="25.77112766484339" CI_END="1.3062570032831322" CI_START="1.1349656266230697" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.217602890215859" ESTIMABLE="YES" EVENTS_1="541" EVENTS_2="596" I2="84.4787544727554" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.11602863186015605" LOG_CI_START="0.05498270875911603" LOG_EFFECT_SIZE="0.08550567030963606" METHOD="MH" NO="2" P_CHI2="3.519132214646614E-5" P_Q="1.0" P_Z="4.0067008271298155E-8" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="997" WEIGHT="100.00000000000001" Z="5.49055615076734">
<NAME>Overall response</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6211012551035917" CI_START="0.9032453713817109" EFFECT_SIZE="1.210062893081761" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.20981014202888879" LOG_CI_START="-0.044194255266203436" LOG_EFFECT_SIZE="0.08280794338134266" ORDER="26800" O_E="0.0" SE="0.14920344031318192" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.02226166660128924" WEIGHT="6.149937681692541"/>
<DICH_DATA CI_END="1.175676213093274" CI_START="0.9832975684288261" EFFECT_SIZE="1.0751928020565553" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="389" LOG_CI_END="0.0702877314096063" LOG_CI_START="-0.007315034792157534" LOG_EFFECT_SIZE="0.03148634830872441" ORDER="26801" O_E="0.0" SE="0.045584249006804106" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.002077923757514321" WEIGHT="57.44864599399242"/>
<DICH_DATA CI_END="2.123642304942687" CI_START="1.3614317940703553" EFFECT_SIZE="1.7003511852502196" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="67" LOG_CI_END="0.3270813683079229" LOG_CI_START="0.13399588864266473" LOG_EFFECT_SIZE="0.2305386284752938" ORDER="26802" O_E="0.0" SE="0.11341936654391177" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.012863952707222213" WEIGHT="13.17891015861276"/>
<DICH_DATA CI_END="1.8457835331427166" CI_START="1.2786438695432973" EFFECT_SIZE="1.5362616310892172" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" LOG_CI_END="0.26618076718067535" LOG_CI_START="0.10674960074991593" LOG_EFFECT_SIZE="0.18646518396529563" ORDER="26803" O_E="0.0" SE="0.09365065635842991" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.008770445436364727" WEIGHT="12.960625032737235"/>
<DICH_DATA CI_END="1.2295304767607504" CI_START="0.8083393361535509" EFFECT_SIZE="0.9969342251950948" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" LOG_CI_END="0.08973929820281873" LOG_CI_START="-0.09240628664898853" LOG_EFFECT_SIZE="-0.0013334942230849045" ORDER="26804" O_E="0.0" SE="0.10699321817713794" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.011447548735900641" WEIGHT="10.261881132965046"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.60379599240254" CI_END="2.2773822555356174" CI_START="1.6525307671199294" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9399598567407492" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="195" I2="78.49901169829249" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.35743593247575567" LOG_CI_START="0.21814955400700956" LOG_EFFECT_SIZE="0.2877927432413826" METHOD="MH" NO="3" P_CHI2="9.400619333730376E-4" P_Q="1.0" P_Z="5.526112644454937E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="997" WEIGHT="100.0" Z="8.099333444751181">
<NAME>Complete remission</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3038493769163937" CI_START="0.6555672154885479" EFFECT_SIZE="1.471698113207547" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5190202395366103" LOG_CI_START="-0.18338277335722752" LOG_EFFECT_SIZE="0.16781873308969134" ORDER="26805" O_E="0.0" SE="0.4125950067248296" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.17023463957426221" WEIGHT="5.14117765758547"/>
<DICH_DATA CI_END="2.050328188225225" CI_START="1.3888782617113344" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="140" LOG_CI_END="0.3118233824837973" LOG_CI_START="0.1426641805223278" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="26806" O_E="0.0" SE="0.09936495258372154" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.00987339380196523" WEIGHT="64.81587612907926"/>
<DICH_DATA CI_END="9.495295148600084" CI_START="2.156396897574983" EFFECT_SIZE="4.525" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="8" LOG_CI_END="0.977508468748251" LOG_CI_START="0.33372869833419344" LOG_EFFECT_SIZE="0.6556185835412222" ORDER="26807" O_E="0.0" SE="0.37815942390247637" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.14300454988625283" WEIGHT="4.933076449384543"/>
<DICH_DATA CI_END="7.060407146847357" CI_START="2.2879427044080556" EFFECT_SIZE="4.019179894179894" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="12" LOG_CI_END="0.8488297458861831" LOG_CI_START="0.3594451444780743" LOG_EFFECT_SIZE="0.6041374451821286" ORDER="26808" O_E="0.0" SE="0.2874669373599695" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.0826372400751206" WEIGHT="8.406251183553076"/>
<DICH_DATA CI_END="1.8565374797686538" CI_START="0.8468690200451168" EFFECT_SIZE="1.2538915727321525" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" LOG_CI_END="0.26870372118534264" LOG_CI_START="-0.07218375409710413" LOG_EFFECT_SIZE="0.09825998354411926" ORDER="26809" O_E="0.0" SE="0.20023899040112625" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.04009565327686233" WEIGHT="16.703618580397652"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="11.112864131707825" CI_END="0.8205889306381358" CI_START="0.6054196819699208" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.7048408965255759" ESTIMABLE="YES" I2="73.00425916807318" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.08587434575955245" LOG_CI_START="-0.21794346439697865" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.15190890507826552" NO="4" P_CHI2="0.011130984654948217" P_Q="1.0" P_Z="6.519830083008945E-6" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" WEIGHT="99.99999999999999" Z="4.508790335789229">
<NAME>Progression-free survival</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours purine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours alkylators</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.6621845504938109" CI_START="0.20033005146555677" EFFECT_SIZE="0.3642189795715233" ESTIMABLE="YES" ESTIMATE="-1.01" LOG_CI_END="-0.17902095604175336" LOG_CI_START="-0.6982538974028154" LOG_EFFECT_SIZE="-0.43863742672228434" ORDER="26810" SE="0.305" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="1" TOTAL_2="1" WEIGHT="6.469609748648732"/>
<IV_DATA CI_END="1.0261197729343325" CI_START="0.6993636158258134" EFFECT_SIZE="0.8471309430481909" ESTIMABLE="YES" ESTIMATE="-0.1659" LOG_CI_END="0.011198056378663446" LOG_CI_START="-0.15529696547416233" LOG_EFFECT_SIZE="-0.0720494545477495" ORDER="26811" SE="0.0978" STUDY_ID="STD-Leporrier-2001" TOTAL_1="1" TOTAL_2="1" WEIGHT="62.92164289920671"/>
<IV_DATA CI_END="0.7862485059948188" CI_START="0.39301101918584047" EFFECT_SIZE="0.555881576124239" ESTIMABLE="YES" ESTIMATE="-0.5872" LOG_CI_END="-0.10444016677888146" LOG_CI_START="-0.40559527276829754" LOG_EFFECT_SIZE="-0.25501771977358945" ORDER="26812" SE="0.1769" STUDY_ID="STD-Rai-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="19.231895804544386"/>
<IV_DATA CI_END="0.8700467931449614" CI_START="0.3531749568208966" EFFECT_SIZE="0.5543272847345071" ESTIMABLE="YES" ESTIMATE="-0.59" LOG_CI_END="-0.060457389383501675" LOG_CI_START="-0.4520100992623354" LOG_EFFECT_SIZE="-0.2562337443229185" ORDER="26813" SE="0.23" STUDY_ID="STD-Robak-2000" TOTAL_1="1" TOTAL_2="1" WEIGHT="11.376851547600156"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.885732264815107" CI_END="1.9543230700054588" CI_START="0.4497796399876227" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9375578525331442" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.29099635872914686" LOG_CI_START="-0.3470002075067743" LOG_EFFECT_SIZE="-0.028001924388813697" METHOD="MH" NO="5" P_CHI2="0.40958073707217235" P_Q="1.0" P_Z="0.8634004173930157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="694" TOTAL_2="936" WEIGHT="100.00000000000001" Z="0.1720472059079824">
<NAME>Therapy-related mortality</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Purine antagonists</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6491823246386805" CI_START="0.007420895069394573" EFFECT_SIZE="0.1402116402116402" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4231118487689715" LOG_CI_START="-2.1295437092418443" LOG_EFFECT_SIZE="-0.8532159302364363" ORDER="26814" O_E="0.0" SE="1.4994425106243536" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="2.248327842667465" WEIGHT="24.24817172812917"/>
<DICH_DATA CI_END="2.3386945583261713" CI_START="0.37967497030384306" EFFECT_SIZE="0.9423076923076923" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.3689735051372876" LOG_CI_START="-0.42058803234985864" LOG_EFFECT_SIZE="-0.025807263606285505" ORDER="26815" O_E="0.0" SE="0.46379235551259407" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.21510334903192047" WEIGHT="64.89505892030337"/>
<DICH_DATA CI_END="78.86106057185263" CI_START="0.13256789052334758" EFFECT_SIZE="3.2333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8968626134347193" LOG_CI_START="-0.8775616543415545" LOG_EFFECT_SIZE="0.5096504795465824" ORDER="26816" O_E="0.0" SE="1.6297105485134018" STUDY_ID="STD-Rai-2000" TOTAL_1="179" TOTAL_2="193" VAR="2.6559564719358533" WEIGHT="3.3034815061240397"/>
<DICH_DATA CI_END="23.224450639218738" CI_START="0.2589586478934781" EFFECT_SIZE="2.4523809523809526" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.365945449805501" LOG_CI_START="-0.5867695811909576" LOG_EFFECT_SIZE="0.3895879343072718" ORDER="26817" O_E="0.0" SE="1.147034475302616" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="1.3156880875327477" WEIGHT="7.553287845443437"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10540206744004062" CI_END="8.906731023171599" CI_START="1.2657453066592947" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3576260944685594" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.9497183371348176" LOG_CI_START="0.10234632571264198" LOG_EFFECT_SIZE="0.5260323314237297" METHOD="MH" NO="6" P_CHI2="0.9486635917566613" P_Q="1.0" P_Z="0.014957093860453834" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="515" TOTAL_2="743" WEIGHT="100.0" Z="2.433416280917221">
<NAME>Haemolytic anaemia</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Purine antagonists</GRAPH_LABEL_2>
<DICH_DATA CI_END="99.81977876234554" CI_START="0.24126127868519828" EFFECT_SIZE="4.907407407407407" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9992166029735117" LOG_CI_START="-0.6175123747458332" LOG_EFFECT_SIZE="0.6908521141138394" ORDER="26818" O_E="0.0" SE="1.5370795545296865" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="2.362613556953179" WEIGHT="10.326074579482672"/>
<DICH_DATA CI_END="13.903906884404218" CI_START="0.8810473273336304" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.1431368506088462" LOG_CI_START="-0.055000761908294796" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="26819" O_E="0.0" SE="0.7037919644694025" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.4953231292517007" WEIGHT="44.642019394127104"/>
<DICH_DATA CI_END="13.476673118985492" CI_START="0.6074167354101176" EFFECT_SIZE="2.861111111111111" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1295826945441967" LOG_CI_START="-0.21651324666842683" LOG_EFFECT_SIZE="0.45653472393788497" ORDER="26820" O_E="0.0" SE="0.7907034191506681" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.6252118970565572" WEIGHT="45.031906026390224"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.5388518909655735" CI_END="2.5839940732815982" CI_START="1.296879824895035" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.830609128483535" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="53" I2="33.90398999422309" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.41229151321466817" LOG_CI_START="0.11289973413880193" LOG_EFFECT_SIZE="0.26259562367673506" METHOD="MH" NO="7" P_CHI2="0.208850909745933" P_Q="1.0" P_Z="5.856880945051253E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="690" TOTAL_2="930" WEIGHT="100.0" Z="3.4381569627121533">
<NAME>Infections (Grade III - IV)</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Purine antagonists</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.71734025791784" CI_START="0.25895400547987113" EFFECT_SIZE="0.9811320754716981" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.570232315029799" LOG_CI_START="-0.5867773669617787" LOG_EFFECT_SIZE="-0.008272525965989885" ORDER="26821" O_E="0.0" SE="0.6796332144921472" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.4619013062409289" WEIGHT="8.868956034245974"/>
<DICH_DATA CI_END="2.4561505974472153" CI_START="0.8420240999695572" EFFECT_SIZE="1.438102220360285" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="28" LOG_CI_END="0.3902549917994152" LOG_CI_START="-0.07467547817492508" LOG_EFFECT_SIZE="0.15778975681224502" ORDER="26822" O_E="0.0" SE="0.27310245950587103" STUDY_ID="STD-Leporrier-2001" TOTAL_1="341" TOTAL_2="597" VAR="0.07458495338815593" WEIGHT="44.71317527544031"/>
<DICH_DATA CI_END="3.160637610344664" CI_START="0.9877681560321642" EFFECT_SIZE="1.7669117647058823" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" LOG_CI_END="0.49977470373269717" LOG_CI_START="-0.005344978865332078" LOG_EFFECT_SIZE="0.24721486243368257" ORDER="26823" O_E="0.0" SE="0.2967098019408369" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="178" VAR="0.08803670656777067" WEIGHT="34.33330410134258"/>
<DICH_DATA CI_END="10.299510299901838" CI_START="1.622022191260617" EFFECT_SIZE="4.087301587301587" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="1.0128165762482562" LOG_CI_START="0.21005679159899998" LOG_EFFECT_SIZE="0.611436683923628" ORDER="26824" O_E="0.0" SE="0.4715450712279945" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.22235475419941442" WEIGHT="12.084564588971146"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3369793574108195" CI_END="1.3356570580739715" CI_START="0.9802597763780571" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1442424957435224" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="259" I2="10.098335090459882" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.1256949634501502" LOG_CI_START="-0.008658817677721727" LOG_EFFECT_SIZE="0.05851807288621425" METHOD="MH" NO="8" P_CHI2="0.34252895626303115" P_Q="1.0" P_Z="0.08776019456511529" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="690" TOTAL_2="930" WEIGHT="100.0" Z="1.7073328988413032">
<NAME>Neutropenia (Grade III - IV)</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Purine antagonists</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7676658659025661" CI_START="0.665251955715744" EFFECT_SIZE="1.0844091360476664" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.2474001756607281" LOG_CI_START="-0.17701384003052723" LOG_EFFECT_SIZE="0.03519316781510046" ORDER="26825" O_E="0.0" SE="0.24930289370030367" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.06215193280734492" WEIGHT="9.417614651862104"/>
<DICH_DATA CI_END="1.267325044515543" CI_START="0.8822035668988915" EFFECT_SIZE="1.0573734792834122" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="202" LOG_CI_END="0.10288801735768419" LOG_CI_START="-0.054431190627692555" LOG_EFFECT_SIZE="0.024228413364995816" ORDER="26826" O_E="0.0" SE="0.09241008151324921" STUDY_ID="STD-Leporrier-2001" TOTAL_1="341" TOTAL_2="597" VAR="0.008539623165285365" WEIGHT="72.11135474620554"/>
<DICH_DATA CI_END="2.0928835928582696" CI_START="0.9588593727455234" EFFECT_SIZE="1.4166089965397923" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" LOG_CI_END="0.32074507335291147" LOG_CI_START="-0.01824508221303343" LOG_EFFECT_SIZE="0.15124999556993898" ORDER="26827" O_E="0.0" SE="0.19912449540776897" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="178" VAR="0.0396505646713986" WEIGHT="16.309826422556792"/>
<DICH_DATA CI_END="6.851111673401497" CI_START="0.7376285201934645" EFFECT_SIZE="2.248015873015873" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8357610465949599" LOG_CI_START="-0.13216229975921606" LOG_EFFECT_SIZE="0.35179937341787193" ORDER="26828" O_E="0.0" SE="0.5685629649462804" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.32326384510850537" WEIGHT="2.161204179375561"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.771127664843384" CI_END="1.306257003283132" CI_START="1.1349656266230697" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2176028902158589" ESTIMABLE="YES" EVENTS_1="541" EVENTS_2="596" I2="84.4787544727554" I2_Q="73.47685600061713" ID="CMP-001.09" LOG_CI_END="0.11602863186015598" LOG_CI_START="0.05498270875911603" LOG_EFFECT_SIZE="0.08550567030963598" METHOD="MH" NO="9" P_CHI2="3.519132214679921E-5" P_Q="0.052170561102302115" P_Z="4.006700827129911E-8" Q="3.7702920891402147" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="997" WEIGHT="100.0" Z="5.490556150767335">
<NAME>Overall response - sensitivity analysis (quality)</NAME>
<GROUP_LABEL_1>Purine Antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.895380096431094" CI_END="1.3389446115738963" CI_START="1.153628152246863" DF="3" EFFECT_SIZE="1.2428371567550143" ESTIMABLE="YES" EVENTS_1="492" EVENTS_2="544" I2="86.89691987045178" ID="CMP-001.09.01" LOG_CI_END="0.12676261182503865" LOG_CI_START="0.062065845690439804" LOG_EFFECT_SIZE="0.09441422875773925" NO="1" P_CHI2="4.2462556431255294E-5" P_Z="1.0621948058753255E-8" STUDIES="4" TAU2="0.0" TOTAL_1="685" TOTAL_2="924" WEIGHT="89.73811886703496" Z="5.720486480214775">
<NAME>Low risk of bias</NAME>
<DICH_DATA CI_END="1.6211012551035917" CI_START="0.9032453713817109" EFFECT_SIZE="1.210062893081761" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.20981014202888879" LOG_CI_START="-0.044194255266203436" LOG_EFFECT_SIZE="0.08280794338134266" ORDER="26829" O_E="0.0" SE="0.14920344031318192" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.02226166660128924" WEIGHT="6.14993768169254"/>
<DICH_DATA CI_END="1.175676213093274" CI_START="0.9832975684288261" EFFECT_SIZE="1.0751928020565553" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="389" LOG_CI_END="0.0702877314096063" LOG_CI_START="-0.007315034792157534" LOG_EFFECT_SIZE="0.03148634830872441" ORDER="26830" O_E="0.0" SE="0.045584249006804106" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.002077923757514321" WEIGHT="57.448645993992415"/>
<DICH_DATA CI_END="2.123642304942687" CI_START="1.3614317940703553" EFFECT_SIZE="1.7003511852502196" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="67" LOG_CI_END="0.3270813683079229" LOG_CI_START="0.13399588864266473" LOG_EFFECT_SIZE="0.2305386284752938" ORDER="26831" O_E="0.0" SE="0.11341936654391177" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.012863952707222213" WEIGHT="13.178910158612759"/>
<DICH_DATA CI_END="1.8457835331427166" CI_START="1.2786438695432973" EFFECT_SIZE="1.5362616310892172" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" LOG_CI_END="0.26618076718067535" LOG_CI_START="0.10674960074991593" LOG_EFFECT_SIZE="0.18646518396529563" ORDER="26832" O_E="0.0" SE="0.09365065635842991" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.008770445436364727" WEIGHT="12.960625032737234"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0767328384829592E-30" CI_END="1.2295304767607504" CI_START="0.808339336153551" DF="0" EFFECT_SIZE="0.9969342251950949" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" I2="100.0" ID="CMP-001.09.02" LOG_CI_END="0.08973929820281873" LOG_CI_START="-0.09240628664898846" LOG_EFFECT_SIZE="-0.0013334942230848559" NO="2" P_CHI2="0.0" P_Z="0.9771055070547895" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="73" WEIGHT="10.261881132965044" Z="0.028697930317278363">
<NAME>High risk of bias</NAME>
<DICH_DATA CI_END="1.2295304767607504" CI_START="0.8083393361535509" EFFECT_SIZE="0.9969342251950948" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" LOG_CI_END="0.08973929820281873" LOG_CI_START="-0.09240628664898853" LOG_EFFECT_SIZE="-0.0013334942230849045" ORDER="26833" O_E="0.0" SE="0.10699321817713794" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.011447548735900641" WEIGHT="10.261881132965044"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.60379599240255" CI_END="2.277382255535618" CI_START="1.6525307671199299" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9399598567407497" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="195" I2="78.4990116982925" I2_Q="81.12159986771182" ID="CMP-001.10" LOG_CI_END="0.3574359324757558" LOG_CI_START="0.21814955400700967" LOG_EFFECT_SIZE="0.28779274324138265" METHOD="MH" NO="10" P_CHI2="9.400619333728155E-4" P_Q="0.0213615207764678" P_Z="5.526112644454778E-16" Q="5.297059035684257" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="997" WEIGHT="100.0" Z="8.099333444751185">
<NAME>Complete remission - sensitivity analysis (quality)</NAME>
<GROUP_LABEL_1>Purine Antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.584287072303608" CI_END="2.476589637147826" CI_START="1.742786589078157" DF="3" EFFECT_SIZE="2.077538737610245" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="168" I2="79.42991669646183" ID="CMP-001.10.01" LOG_CI_END="0.39385405136316437" LOG_CI_START="0.24124420933592033" LOG_EFFECT_SIZE="0.31754913034954235" NO="1" P_CHI2="0.0022086865652078957" P_Z="3.44731506004921E-16" STUDIES="4" TAU2="0.0" TOTAL_1="685" TOTAL_2="924" WEIGHT="83.29638141960234" Z="8.156549414368822">
<NAME>Low risk of bias</NAME>
<DICH_DATA CI_END="3.3038493769163937" CI_START="0.6555672154885479" EFFECT_SIZE="1.471698113207547" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5190202395366103" LOG_CI_START="-0.18338277335722752" LOG_EFFECT_SIZE="0.16781873308969134" ORDER="26834" O_E="0.0" SE="0.4125950067248296" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.17023463957426221" WEIGHT="5.14117765758547"/>
<DICH_DATA CI_END="2.050328188225225" CI_START="1.3888782617113344" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="140" LOG_CI_END="0.3118233824837973" LOG_CI_START="0.1426641805223278" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="26835" O_E="0.0" SE="0.09936495258372154" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.00987339380196523" WEIGHT="64.81587612907926"/>
<DICH_DATA CI_END="9.495295148600084" CI_START="2.156396897574983" EFFECT_SIZE="4.525" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="8" LOG_CI_END="0.977508468748251" LOG_CI_START="0.33372869833419344" LOG_EFFECT_SIZE="0.6556185835412222" ORDER="26836" O_E="0.0" SE="0.37815942390247637" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.14300454988625283" WEIGHT="4.933076449384543"/>
<DICH_DATA CI_END="7.060407146847357" CI_START="2.2879427044080556" EFFECT_SIZE="4.019179894179894" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="12" LOG_CI_END="0.8488297458861831" LOG_CI_START="0.3594451444780743" LOG_EFFECT_SIZE="0.6041374451821286" ORDER="26837" O_E="0.0" SE="0.2874669373599695" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.0826372400751206" WEIGHT="8.406251183553076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8565374797686538" CI_START="0.8468690200451168" DF="0" EFFECT_SIZE="1.2538915727321525" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.26870372118534264" LOG_CI_START="-0.07218375409710413" LOG_EFFECT_SIZE="0.09825998354411926" NO="2" P_CHI2="1.0" P_Z="0.25851430374492257" STUDIES="1" TAU2="0.0" TOTAL_1="69" TOTAL_2="73" WEIGHT="16.703618580397652" Z="1.1299096788956677">
<NAME>High risk of bias</NAME>
<DICH_DATA CI_END="1.8565374797686538" CI_START="0.8468690200451168" EFFECT_SIZE="1.2538915727321525" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" LOG_CI_END="0.26870372118534264" LOG_CI_START="-0.07218375409710413" LOG_EFFECT_SIZE="0.09825998354411926" ORDER="26838" O_E="0.0" SE="0.20023899040112625" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.04009565327686233" WEIGHT="16.703618580397652"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.7711276648434" CI_END="1.3062570032831324" CI_START="1.13496562662307" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2176028902158593" ESTIMABLE="YES" EVENTS_1="541" EVENTS_2="596" I2="84.47875447275541" I2_Q="86.12560476080871" ID="CMP-001.11" LOG_CI_END="0.11602863186015612" LOG_CI_START="0.054982708759116206" LOG_EFFECT_SIZE="0.08550567030963614" METHOD="MH" NO="11" P_CHI2="3.5191322147132276E-5" P_Q="0.007259892571585214" P_Z="4.006700827129691E-8" Q="7.207521356860874" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="997" WEIGHT="100.00000000000001" Z="5.490556150767345">
<NAME>Overall response - sensitivity analysis (type of purine antagonist)</NAME>
<GROUP_LABEL_1>Purine Antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.59579955765543" CI_END="1.2627811878525959" CI_START="1.0843191602991014" DF="3" EFFECT_SIZE="1.1701529119110154" ESTIMABLE="YES" EVENTS_1="432" EVENTS_2="538" I2="81.9231366974655" ID="CMP-001.11.01" LOG_CI_END="0.10132810341287377" LOG_CI_START="0.03515713197677514" LOG_EFFECT_SIZE="0.06824261769482448" NO="1" P_CHI2="8.557375526224709E-4" P_Z="5.2850249049866244E-5" STUDIES="4" TAU2="0.0" TOTAL_1="628" TOTAL_2="894" WEIGHT="87.03937496726277" Z="4.042651029288797">
<NAME>Fludarabine</NAME>
<DICH_DATA CI_END="1.6211012551035917" CI_START="0.9032453713817109" EFFECT_SIZE="1.210062893081761" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.20981014202888879" LOG_CI_START="-0.044194255266203436" LOG_EFFECT_SIZE="0.08280794338134266" ORDER="26839" O_E="0.0" SE="0.14920344031318192" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.02226166660128924" WEIGHT="6.149937681692541"/>
<DICH_DATA CI_END="1.175676213093274" CI_START="0.9832975684288261" EFFECT_SIZE="1.0751928020565553" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="389" LOG_CI_END="0.0702877314096063" LOG_CI_START="-0.007315034792157534" LOG_EFFECT_SIZE="0.03148634830872441" ORDER="26840" O_E="0.0" SE="0.045584249006804106" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.002077923757514321" WEIGHT="57.44864599399242"/>
<DICH_DATA CI_END="2.123642304942687" CI_START="1.3614317940703553" EFFECT_SIZE="1.7003511852502196" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="67" LOG_CI_END="0.3270813683079229" LOG_CI_START="0.13399588864266473" LOG_EFFECT_SIZE="0.2305386284752938" ORDER="26841" O_E="0.0" SE="0.11341936654391177" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.012863952707222213" WEIGHT="13.17891015861276"/>
<DICH_DATA CI_END="1.2295304767607504" CI_START="0.8083393361535509" EFFECT_SIZE="0.9969342251950948" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" LOG_CI_END="0.08973929820281873" LOG_CI_START="-0.09240628664898853" LOG_EFFECT_SIZE="-0.0013334942230849045" ORDER="26842" O_E="0.0" SE="0.10699321817713794" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.011447548735900641" WEIGHT="10.261881132965046"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8457835331427166" CI_START="1.2786438695432973" DF="0" EFFECT_SIZE="1.5362616310892172" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.26618076718067535" LOG_CI_START="0.10674960074991593" LOG_EFFECT_SIZE="0.18646518396529563" NO="2" P_CHI2="1.0" P_Z="4.548295392260748E-6" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="103" WEIGHT="12.960625032737235" Z="4.584612320469169">
<NAME>Cladribine</NAME>
<DICH_DATA CI_END="1.8457835331427166" CI_START="1.2786438695432973" EFFECT_SIZE="1.5362616310892172" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" LOG_CI_END="0.26618076718067535" LOG_CI_START="0.10674960074991593" LOG_EFFECT_SIZE="0.18646518396529563" ORDER="26843" O_E="0.0" SE="0.09365065635842991" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.008770445436364727" WEIGHT="12.960625032737235"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.60379599240254" CI_END="2.277382255535617" CI_START="1.6525307671199294" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.939959856740749" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="195" I2="78.49901169829249" I2_Q="87.01332991041946" ID="CMP-001.12" LOG_CI_END="0.3574359324757556" LOG_CI_START="0.21814955400700956" LOG_EFFECT_SIZE="0.28779274324138254" METHOD="MH" NO="12" P_CHI2="9.400619333730376E-4" P_Q="0.0055214732051400706" P_Z="5.526112644454937E-16" Q="7.700203309255693" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="754" TOTAL_2="997" WEIGHT="99.99999999999997" Z="8.099333444751181">
<NAME>Complete remission - sensitivity analysis (type of purine antagonist)</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.386567855888348" CI_END="2.066816357036872" CI_START="1.4802815497418897" DF="3" EFFECT_SIZE="1.749134105786754" ESTIMABLE="YES" EVENTS_1="213" EVENTS_2="183" I2="68.03943628748127" ID="CMP-001.12.01" LOG_CI_END="0.3153018899467534" LOG_CI_START="0.17034432611802416" LOG_EFFECT_SIZE="0.24282310803238877" NO="1" P_CHI2="0.024569277166086922" P_Z="5.1546842906747276E-11" STUDIES="4" TAU2="0.0" TOTAL_1="628" TOTAL_2="894" WEIGHT="91.5937488164469" Z="6.5663982449356935">
<NAME>Fludarabine</NAME>
<DICH_DATA CI_END="3.3038493769163937" CI_START="0.6555672154885479" EFFECT_SIZE="1.471698113207547" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5190202395366103" LOG_CI_START="-0.18338277335722752" LOG_EFFECT_SIZE="0.16781873308969134" ORDER="26844" O_E="0.0" SE="0.4125950067248296" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.17023463957426221" WEIGHT="5.1411776575854695"/>
<DICH_DATA CI_END="2.050328188225225" CI_START="1.3888782617113344" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="140" LOG_CI_END="0.3118233824837973" LOG_CI_START="0.1426641805223278" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="26845" O_E="0.0" SE="0.09936495258372154" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="588" VAR="0.00987339380196523" WEIGHT="64.81587612907924"/>
<DICH_DATA CI_END="9.495295148600084" CI_START="2.156396897574983" EFFECT_SIZE="4.525" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="8" LOG_CI_END="0.977508468748251" LOG_CI_START="0.33372869833419344" LOG_EFFECT_SIZE="0.6556185835412222" ORDER="26846" O_E="0.0" SE="0.37815942390247637" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.14300454988625283" WEIGHT="4.933076449384542"/>
<DICH_DATA CI_END="1.8565374797686538" CI_START="0.8468690200451168" EFFECT_SIZE="1.2538915727321525" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" LOG_CI_END="0.26870372118534264" LOG_CI_START="-0.07218375409710413" LOG_EFFECT_SIZE="0.09825998354411926" ORDER="26847" O_E="0.0" SE="0.20023899040112625" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.04009565327686233" WEIGHT="16.70361858039765"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.060407146847357" CI_START="2.2879427044080556" DF="0" EFFECT_SIZE="4.019179894179894" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="12" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.8488297458861831" LOG_CI_START="0.3594451444780743" LOG_EFFECT_SIZE="0.6041374451821286" NO="2" P_CHI2="1.0" P_Z="1.3043613042615625E-6" STUDIES="1" TAU2="0.0" TOTAL_1="126" TOTAL_2="103" WEIGHT="8.406251183553074" Z="4.839088238011708">
<NAME>Cladribine</NAME>
<DICH_DATA CI_END="7.060407146847357" CI_START="2.2879427044080556" EFFECT_SIZE="4.019179894179894" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="12" LOG_CI_END="0.8488297458861831" LOG_CI_START="0.3594451444780743" LOG_EFFECT_SIZE="0.6041374451821286" ORDER="26848" O_E="0.0" SE="0.2874669373599695" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.0826372400751206" WEIGHT="8.406251183553074"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.022421963674397" CI_END="1.34427711240728" CI_START="1.1595722971526394" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2485137160815762" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="544" I2="77.43567536990946" I2_Q="65.24206804209784" ID="CMP-001.13" LOG_CI_END="0.12848880442022304" LOG_CI_START="0.06429783126259365" LOG_EFFECT_SIZE="0.09639331784140837" METHOD="MH" NO="13" P_CHI2="6.158482009022137E-5" P_Q="0.08985111340232865" P_Z="3.9465680641348525E-9" Q="2.877041134700339" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="685" TOTAL_2="924" WEIGHT="200.0" Z="5.886417420578638">
<NAME>Overall response - subgroup analysis (stage of disease)</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.325609210496976" CI_END="1.6514228851686217" CI_START="1.1867428821242405" DF="3" EFFECT_SIZE="1.399933696412419" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="137" I2="75.66043228561001" ID="CMP-001.13.01" LOG_CI_END="0.21785829868885265" LOG_CI_START="0.07435663557604281" LOG_EFFECT_SIZE="0.14610746713244774" NO="1" P_CHI2="0.0063470807656264006" P_Z="6.576510608953342E-5" STUDIES="4" TAU2="0.0" TOTAL_1="248" TOTAL_2="299" WEIGHT="100.0" Z="3.991108775190278">
<NAME>High risk (Rai III+IV, Binet C)</NAME>
<DICH_DATA CI_END="4.763499233714897" CI_START="0.9993348051407095" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.6779260996903965" LOG_CI_START="-2.8898658363474185E-4" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="26849" O_E="0.0" SE="0.3983868988961876" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="22" TOTAL_2="16" VAR="0.1587121212121212" WEIGHT="4.993469640562537"/>
<DICH_DATA CI_END="1.3420346988346674" CI_START="0.8888470837208784" EFFECT_SIZE="1.0921829646682013" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="97" LOG_CI_END="0.12776374483268174" LOG_CI_START="-0.051172948150708525" LOG_EFFECT_SIZE="0.03829539834098661" ORDER="26850" O_E="0.0" SE="0.10510829920935895" STUDY_ID="STD-Leporrier-2001" TOTAL_1="103" TOTAL_2="176" VAR="0.011047754562684127" WEIGHT="61.772912896601234"/>
<DICH_DATA CI_END="4.004053096476427" CI_START="1.537708003022281" EFFECT_SIZE="2.4813432835820897" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="16" LOG_CI_END="0.6024998278866586" LOG_CI_START="0.18687387466197303" LOG_EFFECT_SIZE="0.3946868512743158" ORDER="26851" O_E="0.0" SE="0.24414074230582974" STUDY_ID="STD-Rai-2000" TOTAL_1="67" TOTAL_2="70" VAR="0.059604702053641566" WEIGHT="13.49794155792671"/>
<DICH_DATA CI_END="2.025996373800272" CI_START="1.003342576893642" EFFECT_SIZE="1.425751879699248" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="19" LOG_CI_END="0.3066386637093843" LOG_CI_START="0.0014492419460179113" LOG_EFFECT_SIZE="0.1540439528277011" ORDER="26852" O_E="0.0" SE="0.17926977705580366" STUDY_ID="STD-Robak-2000" TOTAL_1="56" TOTAL_2="37" VAR="0.03213765296563755" WEIGHT="19.73567590490953"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.878296689778434" CI_END="1.293907572660363" CI_START="1.102242219177193" DF="3" EFFECT_SIZE="1.194235970945162" ESTIMABLE="YES" EVENTS_1="335" EVENTS_2="407" I2="82.22569459975891" ID="CMP-001.13.02" LOG_CI_END="0.1119032546037586" LOG_CI_START="0.042277041787009195" LOG_EFFECT_SIZE="0.07709014819538391" NO="2" P_CHI2="7.486665940421577E-4" P_Z="1.4238901992085884E-5" STUDIES="4" TAU2="0.0" TOTAL_1="437" TOTAL_2="625" WEIGHT="100.0" Z="4.340144549394783">
<NAME>Low / intermediate risk (Rai 0+I+II, Binet A+B)</NAME>
<DICH_DATA CI_END="1.4207785886908588" CI_START="0.7267270343291836" EFFECT_SIZE="1.0161290322580645" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1525264036122587" LOG_CI_START="-0.13862868370160297" LOG_EFFECT_SIZE="0.006948859955327825" ORDER="26853" O_E="0.0" SE="0.1710259395290886" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="31" TOTAL_2="36" VAR="0.029249871991807466" WEIGHT="6.866415345313461"/>
<DICH_DATA CI_END="1.1788054527745673" CI_START="0.9745885028882866" EFFECT_SIZE="1.0718443177141512" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="292" LOG_CI_END="0.07144213608900779" LOG_CI_START="-0.011178716247999968" LOG_EFFECT_SIZE="0.03013170992050392" ORDER="26854" O_E="0.0" SE="0.04853189764257338" STUDY_ID="STD-Leporrier-2001" TOTAL_1="233" TOTAL_2="412" VAR="0.00235534508878922" WEIGHT="65.22453552359137"/>
<DICH_DATA CI_END="1.8592473368516762" CI_START="1.143384154690826" EFFECT_SIZE="1.4580239862935465" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="51" LOG_CI_END="0.269337168085325" LOG_CI_START="0.05819216935628327" LOG_EFFECT_SIZE="0.16376466872080414" ORDER="26855" O_E="0.0" SE="0.1240276174380393" STUDY_ID="STD-Rai-2000" TOTAL_1="103" TOTAL_2="111" VAR="0.015382849887356631" WEIGHT="15.17838500652207"/>
<DICH_DATA CI_END="1.9550180984140682" CI_START="1.3141315788801577" EFFECT_SIZE="1.6028571428571428" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="40" LOG_CI_END="0.2911507821947905" LOG_CI_START="0.118638851616981" LOG_EFFECT_SIZE="0.20489481690588573" ORDER="26856" O_E="0.0" SE="0.101334361969234" STUDY_ID="STD-Robak-2000" TOTAL_1="70" TOTAL_2="66" VAR="0.010268652915711739" WEIGHT="12.73066412457311"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.943542954239083" CI_END="2.283219191300753" CI_START="1.564449801140678" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8899687324903136" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="148" I2="56.79439128163701" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.3585476061914676" LOG_CI_START="0.1943616323992042" LOG_EFFECT_SIZE="0.2764546192953359" METHOD="MH" NO="14" P_CHI2="0.0737192605093957" P_Q="0.6486182368994321" P_Z="4.102336929630893E-11" Q="0.20764664652808562" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="506" TOTAL_2="769" WEIGHT="200.00000000000003" Z="6.600333568860828">
<NAME>Complete remission - subgroup analysis (stage of disease)</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1410053490281653" CI_END="2.5172845129410177" CI_START="1.2330340498065766" DF="1" EFFECT_SIZE="1.761788159089236" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" I2="53.29297049846629" ID="CMP-001.14.01" LOG_CI_END="0.4009323039143968" LOG_CI_START="0.09097506965244405" LOG_EFFECT_SIZE="0.24595368678342044" NO="1" P_CHI2="0.1434079483012597" P_Z="0.001867734282624632" STUDIES="2" TAU2="0.0" TOTAL_1="170" TOTAL_2="246" WEIGHT="100.00000000000001" Z="3.1104959954117266">
<NAME>High risk (Rai III+IV, Binet C)</NAME>
<DICH_DATA CI_END="2.2781534917213184" CI_START="1.1050922620132702" EFFECT_SIZE="1.5866851595006934" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.3575829815349561" LOG_CI_START="0.04339853794019667" LOG_EFFECT_SIZE="0.20049075973757635" ORDER="26857" O_E="0.0" SE="0.18455349740564006" STUDY_ID="STD-Leporrier-2001" TOTAL_1="103" TOTAL_2="176" VAR="0.03405999340465359" WEIGHT="96.94236572858651"/>
<DICH_DATA CI_END="57.861463261954945" CI_START="0.9243855379515015" EFFECT_SIZE="7.313432835820896" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7623894123495913" LOG_CI_START="-0.03414685769421698" LOG_EFFECT_SIZE="0.8641212773276873" ORDER="26858" O_E="0.0" SE="1.0552942980216942" STUDY_ID="STD-Rai-2000" TOTAL_1="67" TOTAL_2="70" VAR="1.1136460554371002" WEIGHT="3.0576342714135"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.536895918747625" CI_END="2.4280515450166806" CI_START="1.5546042167112128" DF="1" EFFECT_SIZE="1.9428482108170744" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="105" I2="77.95849810290464" ID="CMP-001.14.02" LOG_CI_END="0.38525790212261846" LOG_CI_START="0.1916198413521829" LOG_EFFECT_SIZE="0.2884388717374007" NO="2" P_CHI2="0.03317174446620941" P_Z="5.250373652012634E-9" STUDIES="2" TAU2="0.0" TOTAL_1="336" TOTAL_2="523" WEIGHT="100.00000000000001" Z="5.839035963254053">
<NAME>Low / intermediate risk (Rai 0+I+II, Binet A+B)</NAME>
<DICH_DATA CI_END="2.182467760914707" CI_START="1.3747542394126984" EFFECT_SIZE="1.7321538057283" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="98" LOG_CI_END="0.33894783709226667" LOG_CI_START="0.13822506761611172" LOG_EFFECT_SIZE="0.23858645235418918" ORDER="26859" O_E="0.0" SE="0.11790554838402677" STUDY_ID="STD-Leporrier-2001" TOTAL_1="233" TOTAL_2="412" VAR="0.013901718339738078" WEIGHT="91.31004064078232"/>
<DICH_DATA CI_END="9.130226048464214" CI_START="1.8924369818697295" EFFECT_SIZE="4.156726768377254" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" LOG_CI_END="0.9604815300409104" LOG_CI_START="0.277021426411521" LOG_EFFECT_SIZE="0.6187514782262158" ORDER="26860" O_E="0.0" SE="0.40146784805397956" STUDY_ID="STD-Rai-2000" TOTAL_1="103" TOTAL_2="111" VAR="0.16117643302109322" WEIGHT="8.68995935921769"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.2336845129028" CI_END="1.273554762075961" CI_START="1.1217540385727374" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1952469191352266" ESTIMABLE="YES" EVENTS_1="780" EVENTS_2="596" I2="85.39450231214381" I2_Q="91.4377331714422" ID="CMP-001.15" LOG_CI_END="0.10501762409827997" LOG_CI_START="0.04989764176802457" LOG_EFFECT_SIZE="0.07745763293315226" METHOD="MH" NO="15" P_CHI2="2.139086009655955E-6" P_Q="8.468631172764418E-6" P_Z="3.619072589363306E-8" Q="23.35830031983336" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1090" TOTAL_2="997" WEIGHT="300.0" Z="5.508498532060343">
<NAME>Overall response: different comparators: CAP, CHOP, Chlorambucil</NAME>
<GROUP_LABEL_1>Purine antagonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Alkylators</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Alkylators</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours purine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0033966411378972498" CI_END="1.3710584247242288" CI_START="1.0851908180971612" DF="1" EFFECT_SIZE="1.2197786740165164" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="168" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.13705596171490442" LOG_CI_START="0.03550611049814111" LOG_EFFECT_SIZE="0.08628103610652277" NO="1" P_CHI2="0.9535250684452589" P_Z="8.667891970790747E-4" STUDIES="2" TAU2="0.0" TOTAL_1="389" TOTAL_2="289" WEIGHT="99.99999999999999" Z="3.3305361118967185">
<NAME>CAP</NAME>
<DICH_DATA CI_END="1.6211012551035917" CI_START="0.9032453713817109" EFFECT_SIZE="1.210062893081761" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" LOG_CI_END="0.20981014202888879" LOG_CI_START="-0.044194255266203436" LOG_EFFECT_SIZE="0.08280794338134266" ORDER="26861" O_E="0.0" SE="0.14920344031318192" STUDY_ID="STD-FCG-on-CLL-1996" TOTAL_1="53" TOTAL_2="52" VAR="0.02226166660128924" WEIGHT="15.763247636992165"/>
<DICH_DATA CI_END="1.3877799875925283" CI_START="1.0753136180484855" EFFECT_SIZE="1.2215967908902692" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="138" LOG_CI_END="0.14232062047894936" LOG_CI_START="0.03153514585537258" LOG_EFFECT_SIZE="0.086927883167161" ORDER="26862" O_E="0.0" SE="0.06507593619083284" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="237" VAR="0.004234877471113347" WEIGHT="84.23675236300782"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0936888529603044" CI_START="0.9046701302784484" DF="0" EFFECT_SIZE="0.9946997723392146" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="251" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.03889378574304139" LOG_CI_START="-0.04350974865688219" LOG_EFFECT_SIZE="-0.0023079814569204166" NO="2" P_CHI2="1.0" P_Z="0.9125755656267278" STUDIES="1" TAU2="0.0" TOTAL_1="336" TOTAL_2="351" WEIGHT="100.0" Z="0.10979044929302198">
<NAME>CHOP</NAME>
<DICH_DATA CI_END="1.0936888529603044" CI_START="0.9046701302784484" EFFECT_SIZE="0.9946997723392146" ESTIMABLE="YES" EVENTS_1="239" EVENTS_2="251" LOG_CI_END="0.03889378574304139" LOG_CI_START="-0.04350974865688219" LOG_EFFECT_SIZE="-0.0023079814569204166" ORDER="26863" O_E="0.0" SE="0.04840424401058896" STUDY_ID="STD-Leporrier-2001" TOTAL_1="336" TOTAL_2="351" VAR="0.0023429708382366374" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="14.497310638463752" CI_END="1.6289554362771992" CI_START="1.279385552485408" DF="2" EFFECT_SIZE="1.4436280860441908" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="177" I2="86.20433782598498" ID="CMP-001.15.03" LOG_CI_END="0.21190920337318955" LOG_CI_START="0.10700144212072492" LOG_EFFECT_SIZE="0.15945532274695723" NO="3" P_CHI2="7.11133776924E-4" P_Z="2.5515094446431153E-9" STUDIES="3" TAU2="0.0" TOTAL_1="365" TOTAL_2="357" WEIGHT="100.0" Z="5.958123326550433">
<NAME>Chlorambucil</NAME>
<DICH_DATA CI_END="2.123642304942687" CI_START="1.3614317940703553" EFFECT_SIZE="1.7003511852502196" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="67" LOG_CI_END="0.3270813683079229" LOG_CI_START="0.13399588864266473" LOG_EFFECT_SIZE="0.2305386284752938" ORDER="26864" O_E="0.0" SE="0.11341936654391177" STUDY_ID="STD-Rai-2000" TOTAL_1="170" TOTAL_2="181" VAR="0.012863952707222213" WEIGHT="36.20438842597904"/>
<DICH_DATA CI_END="1.8457835331427166" CI_START="1.2786438695432973" EFFECT_SIZE="1.5362616310892172" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="58" LOG_CI_END="0.26618076718067535" LOG_CI_START="0.10674960074991593" LOG_EFFECT_SIZE="0.18646518396529563" ORDER="26865" O_E="0.0" SE="0.09365065635842991" STUDY_ID="STD-Robak-2000" TOTAL_1="126" TOTAL_2="103" VAR="0.008770445436364727" WEIGHT="35.60472734705086"/>
<DICH_DATA CI_END="1.2295304767607504" CI_START="0.8083393361535509" EFFECT_SIZE="0.9969342251950948" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" LOG_CI_END="0.08973929820281873" LOG_CI_START="-0.09240628664898853" LOG_EFFECT_SIZE="-0.0013334942230849045" ORDER="26866" O_E="0.0" SE="0.10699321817713794" STUDY_ID="STD-Spriano-1999" TOTAL_1="69" TOTAL_2="73" VAR="0.011447548735900641" WEIGHT="28.190884226970095"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.547407337310537" CI_START="1.272803216010568" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8006521739130434" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="138" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.4060983953765497" LOG_CI_START="0.10476126397815341" LOG_EFFECT_SIZE="0.25542982967735156" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="8.913626525289971E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="351" TOTAL_2="237" WEIGHT="100.0" Z="3.32274528812">
<NAME>CHOP versus CAP</NAME>
<GROUP_LABEL_1>CHOP</GROUP_LABEL_1>
<GROUP_LABEL_2>CAP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.547407337310537" CI_START="1.272803216010568" EFFECT_SIZE="1.8006521739130434" ESTIMABLE="YES" EVENTS_1="251" EVENTS_2="138" LOG_CI_END="0.4060983953765497" LOG_CI_START="0.10476126397815341" LOG_EFFECT_SIZE="0.25542982967735156" ORDER="26867" O_E="0.0" SE="0.17700692262627532" STUDY_ID="STD-Leporrier-2001" TOTAL_1="351" TOTAL_2="237" VAR="0.03133145065762422" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 1.0.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 1.1.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 1.2.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-05 15:13:35 +0100" MODIFIED_BY="Nicole Skoetz">
<APPENDIX ID="APP-01" MODIFIED="2008-11-05 15:13:35 +0100" MODIFIED_BY="Nicole Skoetz" NO="1">
<TITLE MODIFIED="2008-11-05 15:13:33 +0100" MODIFIED_BY="Nicole Skoetz">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-05 15:13:35 +0100" MODIFIED_BY="Nicole Skoetz">
<P>#1 the highly sensitive strategy for identifying reports of randomised controlled trials (Cochrane Reviewers' Handbook 4.1.5: 147-146)</P>
<P>#2 Chronic* AND lymph* AND leukaem*<BR/>#3 Chronic* AND lymph* AND leucaem*<BR/>#4 Chronic* AND lymph* AND leukem*<BR/>#5 Chronic* AND lymph* AND leucem*<BR/>#6 "Leukemia, B-Cell, Chronic"[MeSH]<BR/>#7 CLL<BR/>#8 (#2 OR #3 OR #4 OR #5 OR #6 OR #7)</P>
<P>#9 fludara*<BR/>#10 cladribin*<BR/>#11 "Cladribine"[MesH]<BR/>#12 2-Cda<BR/>#13 2Cda<BR/>#14 pentostat*<BR/>#15 "Pentostatin"[MeSH]<BR/>#16 purin* NEXT analog*<BR/>#17 purin* NEXT antagonist*<BR/>#18 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)</P>
<P>#1 AND #8 AND #18</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>